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Abstract
Although the critical role of the small GTPases Ras and Ral in oncogenesis has
been well documented, much remains to be investigated about the molecular mechanism
by which these GTPases regulate malignant transformation. The work under this thesis
made two major contributions to this field. The first is the discovery that K-Ras, RalA
and/or RalB are required for the maintenance of the high levels of the anti-apoptotic
protein survivin in some human cancer cells, and the second is the demonstration that
down regulation of K-Ras, RalA and/or RalB, but not Raf-1 or Akt1/2, stabilizes the
tumor suppressor p53 and reactivates it to inhibit malignant transformation in human
cancer cells with mutant K-Ras and wild type p53. Here we found that depletion of KRas leads to decreased survivin levels in human cancer cells that harbor mutant K-Ras
but not those with wild type Ras. The mechanism by which this occurs involves
ubiquitination and subsequent proteasome-mediated degradation of survivin. The
presence of mutant K-Ras alone was not sufficient to predict the effects of RalA/B
depletion on survivin levels. Indeed, depletion of RalA and/or RalB reduces survivin
levels in human cancer cells with wild type p53 and mutant K-Ras, but not in those with
mutant p53 and/or wild type K-Ras. The functional relevance of these findings to
malignant transformation was further supported by the demonstration that compromising
the expression of survivin by siRNA leads to reduction of mutant K-Ras-driven invasion
and anchorage-independent growth. Furthermore, in this thesis, we have discovered that
down regulation of K-Ras, RalA and/or RalB using siRNA leads to increased levels of

x

functional p53 that is capable of regulating its target genes. The mechanism by which
depleting K-Ras, RalA and RalB increases the levels of p53 involves an increase in the
half-life of the p53 protein concurrent with an increase in the phosphorylation of serine15 of p53, a marker of p53 stability. Finally, we demonstrated that depletion of K-Ras,
RalA and/or RalB interferes with cell cycle progression, anchorage-independent growth
and invasion in a p53-dependent manner. In summary, the studies suggest that mutant KRas contributes to the maintenance of the aberrantly-high survivin levels by regulating its
stability, and that the ability of mutant K-Ras to induce malignant transformation is, at
least in part, dependent of these high levels of survivin. The work of this thesis also
suggests that the expression of K-Ras, RalA and/or RalB proteins is critical to maintain
low levels of p53, and that down regulation of these GTPases reactivates p53 by
significantly enhancing its stability, and this contributes to suppression of malignant
transformation.

xi

Chapter 1

Introduction
Cancer versus normal cells
The transformation of normal cells to cancer cells is thought to arise from gradual
accumulation of multiple genetic alterations such as mutations, chromosomal
translocations and amplifications. These genetic alterations can lead to activation of
cancer-causing genes (oncogenes) such as Ras GTPases and/or inactivation of tumor
suppressor genes such as p53. Pioneering work over the last 3 decades documented that a
single genetic alteration is not sufficient to elicit full-blown transformed phenotype. For
example, Fearon and Vogelstein’s elegant work led to the discovery that colon cancer
develops as a result of successive genetic alterations that are involved in driving
malignant transformation or inhibiting tumor suppression1. These genetic alterations lead
to deregulated signal transduction pathways that in turn result in several hallmarks of
cancers such as apoptosis evasion, invasion, metastasis, resistance to growth suppressors,
sustained proliferative signals, immortality, angiogenesis, evasion of immune destruction
and deregulated cellular energetic2.
Many of the altered genes in cancer cells are intimately involved in signal
transduction pathways that mediate these hallmarks of cancer. For example, mutations in
the Ras gene persistently activate Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral signaling
pathways that mediate many of the hallmarks of cancer including sustained proliferation,
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survival, angiogensis and metastasis2. Up-regulation of the inhibitors of apoptosis (IAPs)
such as survivin and the anti-apoptotic BCL-2 family proteins such as Bcl-xL and Mcl-1
contribute to apoptosis evasion. Amplification of telomerase enables immortality whereas
mutations and/or deletions of the tumor suppressors p53 and RB lead to deregulation of
the cell cycle and enable cells to proliferate continuously2. Furthermore, up regulation of
VEGF-A enables the formation of new tumor blood vessels, loss of E-cadherin promotes
invasion and metastasis, up-regulation of GLUT-4 increase glucose import into the
cytoplasm and

reprogramming of energy metabolism and up-regulation of TGF-β

enables cancer cells to evade immune system by disabling natural killer (NK) cells2.
While the above mentioned mechanism are cited separately, it needs to be emphasized
that the complex crosstalk among the various aberrant signal transduction pathways is
often required for normal cells to trespass the normal control mechanism, acquire certain
hallmarks of cancer and eventually become fully transformed.
Ras, Ral and p53
Ras
Ras is a small GTPase that cycle between GTP and GDP binding states. Active
Ras is GTP bound and capable of transducing signals from surface receptors to the
nucleus to regulate a wide range of cellular processes including differentiation, survival
and motility3. Mutations of Ras are among the most frequently observed mutations in
human cancer. The mutant version of Ras is defective of its intrinsic GTPase activity and
becomes GTP-locked Ras which enables it to stay engaged to its downstream effectors
persistently, and drive malignant transformation3. This prompted many over the last
several decades to target Ras directly and indirectly to discover novel anti-cancer drugs.
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For example, attempts to identify small molecule that can bind Ras either at the GTP
binding site, effector site or allosteric sites and induce a conformational change to reverse
the GTP-lock to the GDP inactive form of Ras were unsuccessful; although renewed
efforts in this area have yielded encouraging results recently4, 5.
An indirect approach to inhibit Ras function that has been investigated
extensively is to prevent Ras from associating with the plasma membrane 6. Ras proteins
undergo prenylation, a type of posttranslational modification, to be able to localize in the
membrane. This localization of Ras on the membrane is required for its activation as well
as for Ras to find and bind its downstream effectors. Previous studies have shown that
this post-translational modification is required for the cancer-causing activity of Ras.
Prenylation is defined as the attachment of a geranylgeranyl or a farnesyl group to the
cysteine of the CAXX box at the C-terminus of Ras by either geranylgeranyl transferase1 (GGT-1) or farnesyl transferase (FT). Since these enzymes transfer the prenyl group to
Ras, it was reasonable to inhibit these enzymes to prevent Ras from localizing to the
membrane. Subsequently, several potent and selective geranylgeranyl transferase
inhibitors (GGTIs) and farnesyl transferase inhibitors (FTIs) have been developed and
shown to inhibit Ras membrane association, Ras-driven oncogenic signaling and
malignant transformation in vitro and tumor growth in mouse models6 . Several FTIs
have been tested clinically and one GGTI has recently entered clinical trials 6.
Unfortunately, the outstanding pre clinical results with FTIs have not translated into
efficacy in human clinical trials, and so far there is no FDA approved FTI that is used in
the clinic. The reasons for this are not well understood. However, the fact that FT has
several hundreds of potential substrates (the human genome encodes about 500 proteins
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that harbor a CAXX box at their C-termini) may contribute to this6. Indeed, at present it
is not know yet which farnesylated proteins are some tumors addicted to. Another reason
may be related to alternative prenylation. For example, among the isoforms of Ras that
are implicated in tumorigenesis, H-Ras is known to undergo farnesylation exclusively,
however, N-Ras and K-Ras have been shown to undergo geranylgeranylation when
human cancer cells are challenged with FTIs7 .
Another indirect approach to inhibit the function of Ras is to target downstream
effectors that have been implicated in cancer. For example, Raf-1 was the first identified
effecter of Ras known to mediate Ras driven malignant transformation. Subsequently,
several Raf-1 kinase inhibitors were developed and many of them showed anti-tumor
activity, however in some tumors, despite complete inhibition of Raf-1 kinase activity,
the tumors still progressed, suggesting existence of other important downstream effectors
that transduce Ras driven transformation8, 9. Indeed subsequent studies identified the
Pi3K/Akt, and RalGDS/Ral and other downstream signaling pathways as critical
effectors that mediate Ras-driven malignant transformation. To date, there are several
inhibitors of these pathways that are in clinical trials6. Ras is known to activate more than
20 downstream effectors and these have been shown to be involved in different
physiological functions of the cell, so the challenge at this moment is to identify the
critical effecters of Ras that human tumors are addicted to. Recent studies have tried to
address this issue using large scale RNAi screen. Using different cell lines that harbor
mutant or wt-K-Ras genes, several target genes were identified, the depletion of which
resulted in selective killing of cancer cells that harbor mutant but not wt K-Ras10-12.
Nonetheless, these studies identified different genes in different cell lines and there was
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no consensus gene the depletion of which induces selective killing of cancer cell with KRas mutation. To date, studies that aim at identifying the critical downstream effectors of
mutant K-Ras continue to be under intense investigation.
Ral
Ral (Ras like) proteins are small GTPases that belong to the Ras family of G
proteins13. As the name indicated, Ral GTPases were first identified when searching for
Ras like genes using oligonucleotide probes that correspond to a sequence of seven
amino acid that are conserved in Ras14. The cDNA library screen from immortalized
simian B-lymphocyte screen identified RalA as a Ras related gene. Using the simian
RalA sequence human RalA and RalB were identified from a phechromocytoma library.
Both RalA and RalB are exclusively geranygeranylated by GGT-1 and this
geranylgeranylation is required for their localization and function15.
Initially, Ral GTPases didn’t get wide attention in cancer because they were found
to have only minor role in Ras driven tumor formation in rodent cells. Later, however, the
Ral guanine exchange factor RalGDS, which activates RalA and RalB, was shown to
directly bind Ras and to play a critical role in Ras-driven tumorigenesis in human cancer
cells of epithelial as well as of fibroblast origin16-20.
Activation of Ral
Like all small G proteins Ral GTPases are GTP/GDP binding proteins that are
active when bound to GTP and inactive when bound to GDP21 . Ral GTPases can be
activated by two major mechanisms: Ras-dependent22-24 and Ras-independent
activation25-27.
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Ras-dependent activation of Ral
Activated Ras can bind directly to several proteins and subsequently induce
activation of numerous downstream effecter pathways that modulate a variety of
biological functions. Activation of the Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral
pathways through direct binding of their up-stream activators has been previously
described3 (see figure 1 below).

P

P

Ras
GEF

s
Ra

Pi3K/Akt

Raf/Mek/Erk

RalGDS
RalGTPase
RalB

RalA
NFkB

c-src

Filamin A

RalBP1

Exoc2

GAP

Cyclin D

pSTAT3

Proliferation/ Activation of
transformation transcription

CDC42/Rac

Elicit actin rich
filapods

Exocyst
regulation

Figure 1. Activation of RalGTPases and their downstream effectors. Upon
activation, RalGDS activates RalA and RalB which in turn modulate
downstream effectors that are involved in the regulation of different cellular
processes.

Guanine nucleotide exchange factors (GEFs) such as Rgl, Rlf and RalGDS28, 29
can activate Ral proteins. Ras activate Ral proteins by binding RalGDS. Structurally
RalGDS has a Ras binding domain (RBD) at its C terminus

30 31

,

which enables it to

interact with Ras. When activated by Ras, RalGDS can then exchange GDP to GTP on
Ral. RBD of RalGDS is critical for Ras-induced activation of RalGDS but activation of
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RalGDS in the absence of RBD domain of RalGDS has also been reported25,

26

.

Linnemann et al show that, RalGDS that lack RBD but artificially targeted to the
membrane, can still be activated by Ras12.
Ras-independent activation of Ral
Activation of Ral independent of Ras has also been described. Hofer et al25 show
that treating Rat-2 cells with Ca2+ activated Ral independently of Ras. The result show
that inhibition of phospholipase C (PLC) blocks Ca2+ induced activation of Ral, implying
that PLC was required for Ca2+ induced activation of Ral proteins25. As suggested by
Hofer et al, the mechanism by which Ca2+ activates Ral could be through phosphorylation
of RalGDS by Calcuim-Calmodulin dependent kinase II or through direct interaction of
Ca2+ with Ral. RalA has calmodulin binding site at its C terminus, and the binding of
Ca2+ facilitate GTP binding to the RalA protein. For Ca2+ dependent activation to occur
geranylgeranylation of Ral and calmodulin interaction are required

32

. Different studies

have also shown that RalGEF undergo posttranslational modification that enables it to
localize in the membrane where it can be activated

33

. RalGEF can also be stimulated

upon association with PI3-K-dependent kinase 1 (PDK1)34. The activation of Ral GEF
activity by PDK1 doesn’t involve its kinase activity, but rather depends on the Epidermal
Growth Factor (EGF)-induced complex formation between PDK-1 and the N terminus of
RalGDS which relieves the auto inhibitory effect on the catalytic domain of RalGDS.
Functions of activated Ral
RalA and RalB are two isoforms that share ~85% overall amino acid sequence
identity and ~100% sequence identity in sequences important for effectors binding14.
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Once activated by RalGEF, they bind to different or similar molecules that play important
roles in cell cycle and transformation35.
Since RalA and RalB share identical effector binding domain,

the two Ral

proteins would be expected to bind to similar molecules and elicit similar functions but
studies so far show that the two Ral proteins do not necessarily bind to same molecules or
elicit same biological outcomes. In fact there are situation where the two proteins are
shown to bind to different effectors and to elicit antagonistic functions.

Figure 2. Role of RalA and RalB in cancer. The small GTPases RalA and
RalB display distinct as well as overlapping functions in cancer.

Significance of Ral protein in human tumorigenesis
Evidence for the importance of Ral in human tumorigenesis started to emerge
when RalGEF was identified as direct interacting protein of Ras and when Ral GDS was
shown to be required for Ras-driven malignant transformation36. Furthermore, other
studies showed that activated Ral was found in human pancreatic cancer cells35 where the
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frequency of K-Ras mutation is also high. Moreover, depletion of Ral protein reduced
Ras ability to transform cells. Similarly, in vivo studies demonstrated that mice deficient
of RALGDS, which is one of Ral GEFs, were developmentally normal but showed
reduced skin tumor growth driven by oncogenic H-Ras

16

. A very recent study showed

that deletion of both RalA and RalB genes inhibit tumor formation37. Other studies also
showed RalA to be the target of known the tumor suppressor phosphatase, protein
phosphates 2A (PP2A)38, 39. Lim et al. also showed that stable knockdown of RalA in
pancreatic cancer cells that harbor mutant K-Ras reduces anchorage independent growth
in soft agar, which further support the role of Ral in transformation35. All in all, these
findings suggest deregulation and significant role of Ral in cancer.
Role of Ral in cell survival
Loss of function studies have shown that depletion of RalB but not RalA initiates
programmed cell death in cancer cell line but there was no effect in normal cell line or
immortalized cell lines. Interestingly, when RalA and RalB are depleted together, this
reverses the death phenotype seen when only RalB is depleted in cancer cells and
immortalized cells that harbor oncogenic H-Ras. This suggested that the two proteins
function antagonistically to regulate cell survival40.
Akt/ protein kinase B (PKB) is one of the survival protein downstream of Ras.
Depletion of RalGDS by RNAi blocks insulin- as well as EGF-induced phosphorylation
of Akt at T-308 and S-473. It is speculated that RalGDS activates Akt by acting as a
scaffold to bring Akt closer to its activator PDK1. In fact shRNA depletion of RalGDS
sensitizes cells to drug-induced apoptosis41. These studies suggest a role of RalGDS in
survival through its ability to modulate Akt activation.
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Role of Ral in cell migration, invasion and metastasis
Another hallmark of cancer is invasion and metastasis. The ability of cancer cells
to invade adjacent tissue and migrate to distant site constitute one of the worst phenotype
of cancer pathogenesis. Therefore, the ability of cells to move helps them to metastasize
to distant site. While RalA but not RalB is critical for Ras driven transformation, RalB
plays critical a role in cell migration. While Rosse et al42 and Oxford et al.43 show that
depletion of RalB but not RalA by siRNA in UMUC-3 (bladder cancer cell line) and DU
145 (prostate cancer cell line) reduces migration, Lim et al

35

show that depletion of

RalA also reduce migration in some pancreatic cancer cells, suggesting the role of Ral in
cell migration could be cell line specific. Nonetheless RalB seem to show dominant effect
in migration. In addition, NIH-3T3 cells that were transformed by Ras effecter mutant
that activate Ral (Ras12V37G) promotes invasion and this was antagonized by over
expressing dominant negative RalB44. High level of activated RalA was also found more
in metastatic cell than their counterpart non metastatic cells33 suggesting the role of
activated RalA in this cancer hallmark.
In-vivo study show that HEK cells transformed by mutant H-Ras form fewer
number of lung metastatic nodules when stably transfected with shRNA to RalA.
Furthermore, even though RalB was dispensable for tumor establishment, cells where
RalB was knockdown by shRNA had significantly impaired metastasis
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. Although

RalA depletion reduces oncogenic Ras driven metastasis, dominant negative RalA had
minimum effect on metastasis in Ras12V37G45. This suggests that RalGTPases require
additional proteins and/or molecules to promote metastasis.

10

Role of Ral in cell cycle
The ability of the body to replace old and dead cells largely depends on cell cycle.
This activity is highly regulated in order to avoid uncontrolled proliferation. Cancer cells
usually become insensitive or evade normal cell cycle control. Cell cycle checkpoints are
important to ensure the completion of previously initiated cell cycle activity before
proceeding with the subsequent steps. Like other signaling protein, Ral proteins have also
been shown to play roles in cell cycle progression.
The two Ral proteins seem to work in collaboration for this activity. RalA
mobilizes the exocyst, to the cytokinetic furrow during the early stage of cytokinesis and
RalB pulls the complex toward the midbody of the cell and drives abscission to complete
cytokinesis46. RalA and RalB share Exo84 and PLD1 as effectors of cytokinesis but RalA
additionally uses Sec5 for early recruitment of exocyst component.
CDK1 is the major mitotic kinase and is regulated by different inhibitory as well
as activating kinases and also phosphatases. The Ras/Ral signaling pathway has been
shown to decrease the inhibitory phosphorylation of cdc2 at Y15 after DNA damage
induced by chemicals. This suggests that Ras/Ral signaling contributes to the activation
of CDK1 and plays a role in mitosis.
Activation of the Ras/RasGDS/Ral pathway inhibits G2 arrest following DNA
damage47. This was demonstrated by showing that dominant negative RalA (N28)
rescues from the loss of G2 arrest that was seen with cells that have activated Ras and
that were treated with the DNA damage agent doxorubicin47.
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p53
p53 is a transcription factor that is known to regulate the expression of different
genes that are involved in cell cycle as well as apoptosis. It is one of the most frequently
mutated genes in cancer with ~50% prevalence in human tumor. It was first identified as
a co-precipitant of SV40-Tag in SV40-infected cells48 and since the co-eluate of the
protein runs at ~53 kilo Dalton in poly-acrylamide gel, the protein was named as p5349.
Since the expression of p53 goes up with SV40 levels in the cell, p53 was considered as
an oncogene50. Subsequently the cloned p53 from transformed cells has been shown to
cooperate with known oncogenes such as H-Ras to transform cells51, 52. Moreover the
cloned p53 by itself was able to immortalize cells 53. However, subsequent studies clearly
demonstrated the tumor suppressive activity of p53 rather than the earlier reported
oncogenic effect54, 55.
Functionally, p53 has been shown to induce cell cycle arrest at G1 and G2/M
phases of the cell cycle as well as apoptosis56. It is now widely accepted that the
molecular mechanism by which p53 accomplish its tumor suppressive activity is through
transactivation or repression of different genes that are involved in apoptosis as well as
cell cycle57, 58.
Even though multiple genetical alterations are required for transformation, few
genes seem to show potent effect at driving or preventing malignant phenotypes, such as
sustained proliferation, resistance to antigrowth and apoptotic signals. Indeed previous
studies have shown that, disabling of p53 function cooperate with Ras to transform
cells59, 60. Moreover, using affymetrix microarrays, McMurray et al found a synergistic
effect on the expression of 95 genes when mutant p53 and Ras are expressed together61.
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The study suggests that p53 and some genes that are regulated by p53 play critical role in
Ras driven transformation.
The following are literature gaps filled by the work of this thesis concerning the
mechanism by which Ral GTPases mediate malignant transformation and the role of the
tumor suppressor p53 in this process.
Although Ral has been shown to have significant role in transformation as well as
in regulating various malignant phenotype, the mechanism by which it regulates these
phenotypes is not known. Furthermore, the ability of mt K-Ras to cause cancer depends
on Ral GTPases, yet the mechanism by which Ral GTPases mediate K-Ras effects is not
known. Recently, mutant K-Ras was shown to down regulate p53 but whether Ral
GTPases down regulate p53 is not known. In this thesis we determined if the expression
of RalA and/or RalB is required for maintaining low levels of wild type p53 in human
cancer cells, and whether the expression of RalA/B is required for persistent degradation
of p53. This thesis also investigated if Ral GTPases regulate the stability of p53 and if
the ability of Ral GTPases to contribute to malignant transformation depends on
suppression of p53.
Survivin and Apoptosis
Cell death
Cells have evolved to respond to proliferative as well as to death signals. Upon
existence of irreparable abnormality, normal cells are doomed to death. Dying cells are
characterized by loss of membrane potential, caspase activation, exposure of
phosphatidylserine residues as well as permeabilization of mitochondrial outer
membrane. However, since these signals can also be detected in the absence of non-lethal
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processes, existence of one signal alone doesn’t represent cell death. So, when is a cell
considered dead? According to the nomenclature committee on cell death (NCCD)
cellular death is defined as the presence of the loss of membrane integrity as defined by
incorporation of vital dyes in vitro, the cell undergo complete fragmentation into discreet
bodies and engulfment of the corpse by adjacent cell in vivo62, 63.
Different types of cell death have been described based on the morphology of the
dying cells and the biochemical events that trigger them. Accordingly, four major types
of cell death exist and these are apoptosis, autophagy, necrosis and cornification.
Morphologically apoptotic cells are presented as rounded cells, fragmented nucleus,
retracted pseudopods, blebbing of plasma membrane and also engulfment of apoptotic
cells by resident phagocytes, in-vivo. Autophagic cells are characterized by massive
cytoplasmic vaculation as well as accumulation of double-membraned autophagic
vacuoles. Necrotic cells show swelling of the cytoplasm and its organelles as well as
rupture of plasma membrane. Cornification is usually seen in skin cells (dermatocytes)
and it is morphologically characterized by elimination of cytosolic organelles,
accumulation of lipids in granules, as well as extrusion of lipids in the extracellular space.
In this thesis, we focus on apoptosis and hence this is further discussed below.
Apoptosis
The term apoptosis was first coined by Kerr et al to describe the specific
morphological change of a dying cell as described above64. Apoptosis occurs during
development, aging as well as normal homeostatic mechanism to maintain the population
of cells. Furthermore, a cell can undergo apoptosis following irreparable damage or
abnormality in the cell.
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The mechanism by which apoptosis is initiated in a cell vary. Some cells express
death receptors, such as TNF-α or Fas in which binding of ligand to its receptor triggers
apoptosis. On the other hand, some cells undergo apoptosis by default but it is prevented
from dying by the binding of growth factor or hormones. In any case, the mechanism by
which apoptosis occurred is highly complex and sophisticated.

To date, two main

apoptotic pathways have been identified: Extrinsic and intrinsic apoptotic pathways. The
extrinsic death pathway is initiated when a death ligand bind to its receptor on cell
membrane, in contrast, the intrinsic pathway is initiated upon cytochrome C release from
the mitochondria. Although this two pathways were identified as two separate pathway
based on how the apoptosis is initiated, subsequent studies show existence of cross-talk
between the two pathways65 (see figure 3).
Biochemical features of apoptosis
Caspases are the major enzymes that are involved in apoptosis. Caspases are
proteolytic enzymes that are capable of degrading proteins by cleaving at aspartic acid
residues. They are widely expressed in a cell in their inactive form. Upon activation, the
activated caspases activate other caspases thereby amplifying the apoptotic cascade and
bringing rapid cell death. To date, 10 major caspases have been identified. They are
majorly classified as initiator caspases (caspase 2, 8, 9 and 10) because they are known to
ignite the caspase activation cascade. The other class of caspases are called effecter
caspases (caspase 3,6, and 7) because they implement the execution phase of the cell
killing. Finally there are other caspase (caspase 1,4, and 5) referred to as inflammatory
caspases61.
Other biochemical features of apoptosis is protein cross linking, which is achieved

15

Ligand
Death
receptor

p53
DNA
damage

Bcl-2 family
proteins
Caspase-8
Cytochrome-c

Mitochondria
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Figure3. Activation of intrinsic and extrinsic apoptosis pathways. Intrinsic
apoptotic pathways can be triggered by many events including DNA damage.
This in turn results in activation of p53 and subsequent upregulation of proapoptotic Bcl-2 family proteins, which form pores in the mitochondrial
membrane through which cytochorme-c is released. The released cytochrom-c
leads to the activation of caspases-9 and -3 and induction of apoptosis.
Alternatively, apoptosis can be triggered through the extrinsic pathway. In this
case, a death ligand binds to its receptor activates caspases-8 and -3 and
induces apoptosis. IAPs can inhibit activation of caspases and this effect could
be antagonized by SMAC, which is also released from the mitochondria.

through activation of tissue transglutaminase66 as well as phagocytosis as a result of
expression of cell surface signals, such as phophatidylserine and annexin that send
signals to phagocytic cells67 also exist.
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The extrinsic pathway
The extrinsic pathway is initiated through activation of a receptor with
transmembrane receptor binding to its ligand. One of the best characterized receptors is
the Fas ligand receptor. This receptor has a death domain “DD” on its cytoplasmic
portion that transmits the death signal from the cell surface to inside the cell61. Upon
binding of a death ligand (FasL) to its receptor (Fas R), the cytoplasmic domain of the
receptor recruits adaptor proteins (FADD). This adaptor protein then recruits procaspase
8 and subsequently forms the DISC (death inducing signaling complex) which results in
auto activation of procaspase-861. Activation of caspase-8 marks the beginning of cell
death. Activated caspase-8 can then activate caspase-3, which is the executioner of cell
death.
The intrinsic pathway
Unlike the extrinsic pathway, the intrinsic pathway is triggered by events that are
not dependent on death receptors such as the Fas ligand receptor. The intrinsic pathway
stimuli include the absence of growth factors or cytokines that normally inhibit cell death.
Other stimuli are exposure to toxins, radiation or viral infection and other agents that
stimulate cell death. The intrinsic pathway is also called the mitochondrial apoptotic
pathway, because the apoptosis executed trough this pathway hinges on mitochondrial
events. The death stimuli induce changes in the mitochondrial membrane which result in
pores that allow the release of mitochondrial proteins such as cytochrome-C and SmacDIABLO61. The cytochorme-C released from the mitochondria binds Apaf-1 and
procaspase-9 to form the apoptosome68, ultimately culminating in the activation of
caspase-9. Also released from the mitochondrial pores is Smac/Diablo, a protein that
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augments apoptosis by inhibiting a family of proteins called Inhibitors of Apoptosis
(IAPs)69.
Execution phase
The execution phase is the final step in apoptosis. In this phase caspases 3,6, and
7 get activated and stimulate different enzymes such as cytoplasmic endonucleases that
degrades nuclear materials and proteases that degrade different nuclear and cytoskeletal
proteins61. Among the three executioner caspases, caspase-3 is considered as the most
important executioner of apoptosis. It gets activated by caspase-9, which is the initiator of
the intrinsic apoptosis pathway as well as by caspase 8, which is the initiator of the
extrinsic apoptotic pathway. Once caspase-3 gets activated, it frees CAD from its
inhibitor (i.e. ICAD). Activated CAD then degrades chromosomal DNA within the nuclei
and cause degradation of chromosomal DNA, chromatic condensation and disintegration
of the cell into apoptotic bodies70.
The BCL-2 family proteins
The Bcl-2 (B-cell lymphoma-2) family members consist of approximately 20
proteins that are known to regulate apoptosis. While some of these members inhibit
apoptosis and hence are termed anti-apoptotic, others promote it and hence are termed
pro-apoptotic proteins. This family of proteins was first considered as proto-oncogene
however since they lack the ability to drive cell proliferation, they are now considered as
proteins that give support to oncogene-driven transformation. Indeed, over expressing
Myc oncogene along with Bcl-2 has been shown to promote the development of
lymphoma as well as other types of cancers71.
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The Bcl-2 family proteins have been classified into three groups based on their
ability to protect or promote apoptosis and the domain they contain in their structure (see
table below). Structurally, the Bcl-2 family of proteins contain up to four Bcl-2
homologue (BH) domains that are designated as BH1, BH2, BH3 and BH472-74. Many of
the anti-apoptotic Bcl-2 family proteins contain all four BH domains while many of the
pro-apoptotic Bcl-2 family members with multi-BH domain contain the first three BH
domains (BH1-BH3), the remaining pro-apoptotic proteins harbor only the BH3 domain.
(see table below)
Table 1. Classification of Bcl-2 family proteins

Bcl-2 family proteins with multiple BH domains

BH3 only proteins

Anti-apoptotic

Pro-apoptotic

Pro-apoptotic

Bcl-2

Bax

PUMA

Bcl-XL

Bak

Bid

Bcl-W

Bok

Noxa

Mcl-1

Bad

Bcl-B

Blk

A1

Bim
HRK
BMF

Mechanism of apoptosis regulation by Bcl-2 family proteins
Apoptosis can be triggered by an insult to a cell. Upon such stimuli, the cell can
be programmed to die. Bcl-2 family proteins have been shown to promote or inhibit
apoptosis. Multitude of studies have shown that the Bcl-2 family proteins regulate
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apoptosis through their ability to regulate the intrinsic apoptotic pathway, also called
mitochondrial apoptotic pathway, by regulating membrane permeabilization of the
mitochondria75.
The anti-apoptotic bcl-2 family proteins are found majorly bound to
mitochondria, endoplasmic reticulum as well as nuclear membranes75-78. The proapoptotic proteins on the other hand are found primarily in the cytoplasm or bound to the
cytoskeleton61. Following death signal, pro-apoptotic proteins such as Bax and Bak not
only translocate to the mitochondria but they also undergo conformational changes that
enable them to be inserted into the mitochondrial membrane79, 80. For example, Bax has
been shown to insert itself into the outer mitochondrial membrane using its c-terminal
membrane anchor81. This step forms pores on the mitochondria that result in release of
apoptogenic molecules such as cytochrome c as well as SMAC eventually resulting
caspase activation as described above82. The anti-apoptotic proteins on the other hand
protect permeabilization of the mitochondrial membrane by binding and antagonizing the
pro-apoptotic proteins.
The BH3 only proteins also induce apoptosis through their interaction with Bcl-2
family proteins. Furthermore, studies have shown that some BH3 only proteins, such as
Bim or Bid, can interact with Bax and synergize at increasing cell-free permeabilization
of membrane, which suggest that some BH3 induce apoptosis not only by interacting
with anti-apoptotic proteins but also by interacting with pro-apoptotic proteins.
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IAP family proteins
IAPs are another family of protein that is known to inhibit apoptosis. IAPs were
first discovered by Lois Miller and her colleagues in baculovirus

83, 84

. They were shown

to inhibit cell death following viral infection.
Expression of human IAPs
Eight human IAPs have been identified in human cells and these are NAIAP, cIAP1, c-IAP2, XIAP, survivin, Livin, bruce and ILP85-89. The expression of many IAPs
but that of survivin has been detected in many normal adult tissue61. Overexpression of
IAP family proteins (XIAP, c-IAP1 and c-IAP2 or survivin) has been shown to inhibit
apoptosis induced by a variety of stimuli that include withdrawal of growth factors,
apoptosis-inducing ligand such as Fas as well as drugs such as staurosporin and etoposide
86, 87, 90, 91

.
Mechanism of apoptosis inhibition by IAP family proteins

Several studies investigated the mechanism by which IAPs inhibit apoptosis.
Many studies show that XIAP, c-IAP1 and c-IAP2 and survivin inhibit directly92-94 the
activities of caspases 3, 7 and 9 but not 1,6,8,or 10. While IAPs are capable of binding to
pro-caspase 9 in vitro and inhibits activation of caspase 9 by cytochrome c94 they were
shown to bind only to active caspase 3 and 7

92, 93, 95

. Co-expression of c-IAP1 and c-

IAP2 or survivin with caspase 3, 7, 9 were shown to reduce the ability of caspases to
induce apoptosis.
IAPs contain BIR (baculoviral IAP repeat) domains, and depending on the IAP
protein, they may contain additional domains such as RING or caspase recruiting domain
(CARD) IAPs contains one to three copies of BIR domain, which is a ~70 residue zinc

21

binding domain. The BIR domain is considered the defining structural characteristics of
IAP and all members of IAPs contain at least one BIR domain96-99. The BIR domain is
essential for the anti-apoptotic function of IAP proteins92, 93, 100, 101
Some IAPs (XIAP, ILP-2, c-IAP1 and c-IAP2 as well as livin) also contain a
RING domain, which is another zinc binding motif. Studies have shown that the RING
domain of IAPs functions as a ubiquitin ligase that leads the auto-degradation as well as
the degradation of other target proteins.
cIAP1
cIAP2
XIAP
NIAP

cIAP1
cIAP2

BIR3

CARD

cIAP1
cIAP2
XIAP
pIAP

pIAP

BIR1

BIR2

BRUCE
Survivin

RING

UBC
BRUCE

Figure 4. Structure of IAPs. IAPs contain the BIR domain, which is the
defining structure for this family of proteins. Survivin, which is the smallest
IAP family protein and BRUCE contain only one BIR domain, where as pIAP
contain 2 BIR domains and cIAP1, cIAP2, XIAP and NIAP contain three BIR
domains. cIAP1 and cIAP2 contain caspase recruiting domain (CARD) and
RING domain in their structure. BRUCE also contains the ubiquitin
conjugating domain.

BIRs function to inhibit apoptosis majorly by mediating protein-protein
interactions. In IAPs that contain more than one BIR, the second and third BIR domains
have been shown to bind caspases and regulators of apoptosis61 but BIR-1 has been
shown to interact with signaling intermediates. Overexpressed XIAP BIR1 interacts with
TGF-B activating kinase 1 (TAK-1) associating subunit 1(TAB1) which then activate
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MAPK signaling102. Although survivin harbors only one BIR domain, it has been shown
to interact with Aurora B through its BIR domain103. In addition, BIR1 domain has been
shown to interact with other IAP, Eg. XIAP BRI1 interacts with survivin upon apoptosis
stimuli61.
IAPs and apoptosis
All IAPs were initially believed to inhibit apoptosis. This observation came from
studies that overexpression of IAPs, i.e survivin, c-IAP1 and c-IAP2 as well as XIAP
inhibits caspase 3, 7 and 9. Later, however, it was shown that only XIAP was capable of
inhibiting caspases 3, 7, and 961. XIAP was shown to bind and inhibit the activation of
caspases61. The BIR3 domain of XIAP binds to caspase 9 and the BIR-2 domain binds to
caspase 3 and 7104.
Survivin
Survivin is a member of the IAP family of proteins with dual function in
apoptosis and cell proliferation105. What makes survivin unique is its over-expression in
most tumors with very little expression in normal cells90, 106. Indeed studies have found
high levels of survivin protein in fetal tissue but almost undetectable in most adult
tissue90.
The survivin gene is located on the 17q25 chromosome in humans91. It undergoes
alternative splicing and it gives rise to five transcripts. The wild-type survivin is derived
from exons 1-4 and has 142 amino acids. The other isoform of survivin, 2B, harbors an
additional segment in its exon 2. The third isoform, survivin ∆EX3, has 137 amino acids
because of removal of exon 3107. Survivin 2 alpha is another transcript that contains exon
1 and exon 2 and some regions of intron-2 which resulted in acquisition of new a stop
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codon and a shorter survivin that has only 74 amino acid108. Also another transcript
which is termed as survivin 3B is encoded by exons one to three and a new DNA
sequence from intron 3 of survivin resulting in a protein with 113 amino acids109.
Although different studies investigated the localization and function of the different
isoforms of survivin, the wild-type survivin is the most studied isoform of survivin.
Structure of survivin
Survivin is the smallest of all human IAPs and contains only one BIR domain and
an extended C-terminal alpha helix61. X-ray crystallography of survivin show that it
forms a stable homodimer in solution110, 111.
Expression of survivin in cancer and regulation of its expression
Survivin is differentially expressed in cancer112, and except for few normal cells,
i.e thymocytes, CD34+ stem cells as well as basal colonic epithelial cells, it is
undetectable in most terminally differentiated adult tissue 61. This differential expression
has also been confirmed by the result from a genome wide search that show survivin as
the fourth most expressed transcriptom in cancer106. High expression of survivin in
cancer has been reported in tumors of colon, breast, lung, pancreas, esophagus, stomach,
liver, ovary, melanoma, neuroblastoma and other types of cancer61.
How the expression of survivin is upregulated in cancer is not clearly understood
but some studies shed light about the molecular mechanism. For example, while survivin
exon1 is highly methylated in normal ovarian epithelium, in most ovarian cancer, it is
found unmethylated and transcriptionaly active61. Also gain of 17q25 in neuroblastoma61,
negative regulation of survivin61 and loss of wild-type p53 in many human tumors
suggest possible mechanism by which survivin could be upregulated in cancer.
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Several studies show the correlation between increased tumor survivin expression
and unfavorable patient prognosis or decreased overall survival. High levels of survivin
have been correlated with decreased patient survival in lung , gastric, colorectal, breast
cancers and neuroblastoma61. Also, increased survivin expression is associated with
increased risk of recurrence and metastasis in laryngeal carcinoma as well as
osteosarcoma patients61. In addition to this, survivin could be a predictive marker to
chemotherapy and radiotherapy resistance61
Regulation of survivin expression
Survivin is expressed constitutively in cancer with peak expression at the G2/M
phase of the cell cycle61. The survivin promoter harbors cell cycle dependent elements
(CDE) and cell cycle gene homologue region (CHR) and is believed to play role in the
cell cycle regulated expression of survivin61.
The transcription of survivin in cancer is believed to be regulated by several
transcription factors. For example, studies have shown that the signal transducer and
activator of transcription (STAT-3)61 and E2F61 positively regulate survivin expression.
Over expression of dominant negative STAT-3 or pharmacological inhibition of STAT-3
has been shown to reduce the transcription of survivin61. Similarly, the tumor suppressers
p5361 and APC61 negatively regulate survivin expression.
Beside the transcriptional regulation of survivin, post-translational modifications
of survivin have been shown to regulate the expression of survivin. Survivin has been
shown to undergo phosphorylation at Thr-34, which is believed to inhibit survivin
degradation by the proteasome. The only known kinase to phosphorylate Thr-34 is
cyclin-dependent kinase 1 (CDK1)61. This kinase is active at the G2/M phase of the cell
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cycle, therefore it is possible to speculate that beside the CDE/CHR role, this
phosphorylation could be responsible for the higher survivin expression levels at G2/M.
Indeed, co-immunoprecipitation of survivin with CDK1 from cells that were
synchronized at G2/M has been demonstrated and over expression of kinase dead CDK1
resulted in lower phosphorylation of survivin at this amino acid residue.
Role of survivin in cell cycle and apoptosis
The role of survivin in the regulation of cell cycle and apoptosis has been under
intense scrutiny. With regards to cell cycle regulation, survivin as a member of the
chromosomal passenger complex (CPC) is involved in the regulation of cell division
through its association with INCENP and Aurora B on the centromere61. RNAi mediated
depletion of survivin leads to impaired localization of the CPC at the centromere and
mitotic spindle which resulted in interference with mitotic progression. Also, other
studies have shown that siRNA mediated depletion of survivin resulted in the absence of
aurora B and INCENP from centromere, misaligned chromosomes and in multi-nucleated
cells61. In addition, in vitro studies showed that the G2M kinase Aurora B phosphorylates
survivin at Thr-117.
Role of survivin in apoptosis
The evidence for the ability of survivin to inhibit apoptosis comes from different
studies that were done both in-vitro as well as in-vivo. Several studies have shown that
survivin is able to protect cells from extrinsic and intrinsic mediators of apoptosis
including withdrawal of interleukins, stimulation with Fas ligand, over expression of proapoptotic proteins such as p53, Bax, caspase 3 and 890, 94, 107, 113-116. Additional evidence
for survivin’s role in apoptosis comes from the observation that using survivin dominant
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negative mutants, ribozymes, anti-sense as well as siRNA induces spontaneous apoptosis
in vivo117-124. Also, transgenic mice that express survivin at the basal layer of the
epidermis using cytokeratin-14 promoter block apoptosis induced by UV irradiation125.
Although the above studies convincingly demonstrate the anti-apoptotic role of
survivin, the exact molecular mechanism by which survivin interfere in apoptosis is not
known. Different studies have shown association of survivin with initiator and effector
caspases 94, 126, 127 however whether survivin inhibit caspase activation is uncertain128-130 .
For example, while Tamm et al found that cellular survivin inhibits caspases, chemically
synthesized survivin fails to do so. However, from x-ray crystallography structural
studies, it is now clear that except for XIAP, all other IAPs lack the structure features to
inhibit caspases61.
The following are literature gaps filled by the work of this thesis concerning the
mechanism by which cancer cells maintain high levels of the survivin protein and the
contribution of the Ras and Ral GTPases in this process.
The high levels of survivin in cancer cells and the lack of expression in most
normal tissues strongly suggest that some of the genetic alterations of cancer cells result
in up regulation of survivin. While activation of STAT3, NFkB, Notch and Wnt as well
as inactivation of the tumor suppressors p53 and Rb all have been shown to increase
survivin expression, little is known about the regulation of survivin by the GTPases Ras
and Ral. In this thesis, we investigated whether the expression of mutant K-Ras is
required for the maintenance of the high levels of survivin in human tumors. We also
determine whether K-Ras depletion attenuates both basal and drug-induced survivin
levels. We also determined the mechanism by which K-Ras depletion decreases survivin
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levels by investigating the phosphorylation, ubiquitination and proteasomal degradation
of survivin. Furthermore, we investigated whether depletion of RalA, RalB, Raf-1, Akt1
or Akt2 decreases survivin levels. Finally, we evaluated whether the ability of mutant KRas to induce anchorage-independent growth, invasion and survival is compromised by
depletion of survivin.
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Chapter 2

K-Ras requirement for survivin stability and survivin contribution to K-Ras driven
malignant transformation

Note to Readers
Portion of these results have been previously published (Awet Tecleab and Said
Sebti, Cell Cycle 12:3, 522–532; February 1, 2013) and are utilized with permission of
the publisher.

Abstract
Mutant K-Ras and high levels of survivin contribute to oncogenesis but little is
known about K-Ras requirement for survivin maintenance and survivin contribution to
K-Ras-driven malignant transformation.

Here we demonstrate that K-Ras depletion

significantly decreases survivin levels in human cancer cells that harbor mutant but not
wild K-Ras. K-Ras depletion also suppresses the ability of drugs such as paclitaxel and
VP16 to induce survivin levels. The mechanism by which K-Ras depletion decreases
survivin levels is through ubiquitination and proteasomal degradation of survivin, and is
independent of survivin-Thr-34 phosphorylation. Furthermore, the ability of mutant KRas to induce anchorage-independent growth, invasion and survival is compromised by
depletion of survivin.

These studies suggest that mutant K-Ras contributes to the
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maintenance of the high survivin levels by regulating its stability, and that the ability of
mutant K-Ras to induce malignant transformation is at least in part dependent on
survivin.
Keywords: Apoptosis / Cancer / K-Ras / Protein degradation / Survivin
Introduction
One of the critical requirements for normal cells to become cancerous is to
acquire the ability to evade programmed cell death (apoptosis) even when challenged
with unfavorable conditions such as cytotoxic agent or radiation exposure 1. The Bcl-2
family as well as and the inhibitors of apoptosis (IAP) family of proteins play essential
roles in the regulation of apoptosis. While the Bcl-2 family proteins monitor cell death by
controlling the release of cytochrome c from mitochondria, the IAP family proteins
prevent cell death by inhibiting the activation of caspases2, 3. Survivin is one of the
members of the IAP family known to play critical roles in promoting cell cycle
progression

4

and in preventing apoptosis5. During cell cycle progression, survivin

mediates proper loading of the chromosomal passenger complex, chromosomal
segregation, spindle formation and microtubule stabilization6, 7. The role of survivin as an
anti-apoptotic protein has also been investigated thoroughly, and depending on the cell
type, survivin inhibits either spontaneous apoptosis or drug-induced apoptosis8. Despite
its prominent role in apoptosis, the mechanism by which survivin blocks apoptosis
remains elusive. Some studies suggested that survivin protects against apoptosis through
direct binding to caspases 5 whereas other studies demonstrated that XIAP (another IAP
member) but not survivin directly binds caspases9. More recent studies demonstrated that
survivin binds and cooperates with XIAP to efficiently block caspase activation10.
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Unlike other IAPs, little to no survivin is expressed in normal cells. In contrast,
virtually all cancer cells maintain very high levels of survivin protein11. The fact that
survivin protein levels are much higher in cancer cells as compared to normal cells
indicates that some oncogene may be responsible for the maintenance of these high
levels. In deed, the induction of survivin expression in cancer cells has been attributed to
some mutated or deregulated oncogenes/ proto-oncogenes in cancer. For example,
aberrant activation of STAT3, NFkB, Notch and Wnt as well as inactivation of the tumor
suppressors p53 and Rb all have been shown to increase survivin expression by
regulating its transcription 12.
Mutations in the small GTPase Ras and high levels of the survivin protein are
prevalent in human tumors but the role of mutant Ras in regulating survivin protein levels
has not been thoroughly studied, and the very few studies reported, investigated mainly
the role of ectopically expressed H-Ras but not K-Ras, the most frequently mutated
isoform of Ras in human cancer. Previous studies showed that, ectopic over expression
of c-H-Ras in Rat cells as well as in human keratinocytes induces survivin expression
14

13,

. Furthermore, Fukuad et al. showed that exogenous H-Ras is required for interleukin

induced survivin in Baf-3 cells

15

. However, other studies showed that mutant H-Ras is

not able to increase survivin16. Furthermore, the requirements of endogenous Ras for the
maintenance of the high levels of survivin in cancer cells have not been investigated.
Finally, several studies have documented both in vitro and in vivo the importance of
survivin to malignant transformation

17, 18

but little is known about the contributions of

survivin to mutant K-Ras-driven transformation.
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In this thesis, we demonstrated that depletion of K-Ras decreases survivin levels
in human cancer cells that harbor mutant K-Ras but not wild type Ras, and that this
decrease in the survivin protein levels is due to proteasome degradation, suggesting that
mutant K-Ras regulates survivin stability. Furthermore, we also demonstrated that
depletion of survivin significantly reduces mutant K-Ras-driven anchorage-independent
growth and invasion suggesting that survivin contributes to K-Ras driven malignant
transformation.
Materials and Methods
Cell culture
The human tumor cell lines were grown in their respective media: A549 in
Kaighn's modification medium (F12K) (Gibco Laboratories, Grand Island, NY), Calu-1
and SKOV-3 in McCoy’s 5a medium modified (Sigma-Aldrich, St. Louis, MO), H460,
AsPC-1, Ovcar-5 and BxPC-3 in RPMI, (Invitrogen, Carlsbad, CA), MiaPaCa-2, Panc-1,
SW1990, and HOP-92 in Dulbecco’s modified minima essential medium (DMEM)
(Invitrogen). All cells were grown in their respective media containing 10% FBS and 1%
penicillin streptomycin at 37oC in a humidified incubator at 5% CO2. Human Pancreatic
Nestin Expressing (HPNE) cells were the kind gift of Dr Channing Der and Dr Paul
Campbell (University of North Carolina) and were maintained in media containing 3:1
mixture of DMEM and M3F base media (INCELL, San Antonio, TX). NIH-3T3 cells
that stably express mutant K-Ras and C7 cells that stably express mutant K-Ras were
grown as described by us 19, 20 respectively.
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siRNAs and antibodies
Non-targeting (NT) and K-Ras siRNA were purchased from Dharmacon,
Lafayette, CO and Ambion, Grand Island, NY, respectively. Survivin antibodies were
purchased from Novus biologicals, Littleton, CO (used for immunoprecipitation), and
Abcam, Cambridge, MA (used for western blotting). Bax, MCL-1, Bad and ubiquitin
antibodies were purchased from SantaCruz Biotechnology Santa Cruz, CA. Cleaved
PARP antibody was purchased from Cell Signaling, (Danvers, MA). β-actin, vinculin, αtubulin and GAPDH antibodies were purchased from Sigma. K-Ras (OP-24), Bcl-2 and
Bcl-XL antibodies were purchased from Calbiochem, Billerica, MA. XIAP antibody was
purchased from BD Biosciences, San Jose, CA. Peroxidase conjugated Goat anti-mouse
IgG, Rabbit anti-Goat IgG, Mouse anti-Rabbit IgG antibodies were purchased from
Jackson immunoResearch Laboratories, West Grove, PA. TrueBlot mouse secondary was
purchased from e-Bioscience San Diego, CA.
DNA constructs and site directed mutagenesis
Survivin T34 mutants were generated using QuickChange II XL site directed
mutagenesis kit (Agilent Biotechnologies, Santa Clara CA). Survivin ORF plasmid was
purchased from Origene and used as a template to do site directed mutagenesis according
to the manufacturer’s recommendation. Briefly, primers were designed using an online
primer designing tool from Agilient Biotechnology, www.agilent.com/genomics.
The following primers were purchased from Integrated DNA Technology (IDT).
Survivin T34D:

Sense primer: 5’-GGGCTGCGCCTGCGACCCGGAGCGGATG-3’;

Antisense primer: 5’-CATCCGCTCCGGGTCGCAGGCGCAGCCC-3’.
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Survivin

T34A : Sense primer: 5’-GCTGCGCCTGCGCCCCGGAGCGG-3’ ; Antisense primer:5’-CCGCTCCGGGGCGCAGGCGCAGC-3’.
PCR conditions:

The following components were added into a PCR tube-

reaction buffer to 1X, 200ng DNA, 125ng of each sense and antisense primers, 1ul of
dNTP mix, 3ul of quicksolution and distilled water to a final volume of 50ul and DNA
polymerase (all reagents from Agilent Biotechnologies). PCR cycle conditions: 95oC2min, 95oC-1min, 60oC-50 sec, 68oC 14min, 68oC 7min, repeat 18 times then end.
Following temperature cycling, the reaction tubes were placed on ice for 2min, followed
by the addition of 2 μL DPN1 restriction enzyme to each sample. This reaction was
allowed to go for at least 4 hr at 37oC. After generation of the plasmid, bacteria (XL10Gold Ultra competent Cells) were transformed per the manufacturer’s instructions. After
overnight incubation, 10 colonies were picked for each sample. DNA was purified to
determine mutation status.
Cloning of myc-tagged CA-K-Ras12V
We used our previously described K-Ras-Q12V pBABE expression construct
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as template to clone into myc-tagged pCMV-Tag3B vector. The following primers were
used to shuttle the construct:
Forward primer: 5’-CGC GGA TCC AAG CTT ATG ACT GAA TAT AAA CTT GTG
GTA-3’,
Reverse primer: 5’-TGC TCT AGA CTC GAG TTA CAT AAT TAC ACA CTT TGT
CTT-3’
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siRNA transfection
Cells were transfected with siRNA using Lipofectamin RNAiMAX transfection
reagent (Invitrogen) according to the manufacturer’s instructions. Briefly, cells were
plated overnight to reach ~40-50% confluence at the time of transfection. Lipofecatmine
RNAiMAX and Optimum were mixed in one tube and a mixture of siRNA and Optimum
was prepared in another tube, and the content of the two tubes were mixed. The mixture
was incubated for 20 min at room temperature, after which the siRNA-RNAiMax mixture
was added to cells drop-wise. After 24 hrs of transfection, appropriate media that contain
10% serum only was added until the desired time of transfection.
DNA transfection and generation of stable cell lines
Cells were plated overnight to reach 70-80% confluence and were then
transfected with DNA using Lipofectamine 2,000 transfection reagent according to the
manufacturer’s instructions. Briefly, Lipofectamine 2,000 reagent (1.5μl/μg of DNA)
was diluted in OPTI-MEM medium (Invitrogen) and allowed to equilibrate for 5 min at
room temperature. 2μg of DNA (vector or Myc-DDK-survivin construct), (Origene,
Rockville, MD) was diluted in OPTI-MEM in a separate tube. The contents of the two
tubes were mixed and allowed to complex for 20 min at room temperature, and added
drop wise to cells that contain 10% FBS but no 1% PS. The cells were transfected for 6
hrs before changing the medium to medium containing 10% FBS only and incubated for
an additional 18 hrs. The medium was then replaced with complete growth medium
containing 1.2mg/mL of G418 (Fisher Scientific, Pittsburgh, PA). The cells were kept in
selection medium for 2 weeks after which the resistant cells were pooled and grown for
further experiments.
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Western blotting
Cells were rinsed with ice cold PBS twice and lysed on the plate in lysis buffer
containing 20mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium
orthovanadate, 1ug/mL leupeptin, and 1 mM PMSF. The lysate was collected by scraping
and centrifuging at 13000g for 13 min to remove the debris. The protein content was
measured using Bradford protein assay. Samples were resolved using 12.5% SDS-PAGE
and transferred to PVDF membranes (Millipore, Billerica, MA). The membranes were
blocked with 5% milk in Tris-Buffered Saline and Tween 20 (TBST) and then probed
with the desired antibodies. The enhanced chemiluminescence blotting system
(PerkinElmer Inc, Waltham, MA) was used for antibody reaction.
Immunoprecipitation
Cells were rinsed with ice cold PBS twice and lysed on the plate in NP-40 lysis
buffer containing 20 mM Tris pH 7.5, 0.05% Igepal, 250mM NaCl, 3mM EGTA, 3mM
EDTA, 2mM NaVO4, 2mM PMSF

and 7.4mg/ml PNPP, 0.5uM bortezomib, Ub-

aldehyde 4μM, 20mM n-ethylmaleimide. After collecting the lysate, the lysate was
sonicated (4 pulses), using Branson Sonifier, VWR Scientific, at output level 3, duty
cycle (%) 30. After clearing the debris by centrifuging at 13,000g for 13minutes, the
protein amount was measured. 600-1000μg of protein was incubated with 30μl of 50/50
mix of protein A/ protein G agarose beads (Millipore) and 2μg/ml of survivin antibody
(Novus) at 4oC overnight on an orbital shaker. After overnight incubation, the sample
was centrifuged for 5 second to collect the beads. The supernatant was discarded and the
beads were washed two times with 500μl lysis buffer. The agarose beads were re-
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suspended in 30ul of sample buffer. The agarose beads were boiled for 5minutes to
dissociate the immunocomplex from the beads. The beads were collected by centrifuging
and the proteins in the supernatant were run on a 12.5% SDS-PAGE.
In-vivo ubiquitination assay
Panc-1 cells were first transfected with siRNA for 48hr. The cells were then
treated with 0.5uM of bortezomib (Velcade) for 30min. The cells were then lysed with
NP-40 lysis buffer. Survivin was immunoprecipitated as described above and
ubiquitinated survivin was detected using ubiquitin antibody from SantaCruz
Biotechnology and TrueBlot mouse secondary (eBioscience).
Caspase activation assay
Caspase-3 activity was measured in cell lysates using a fluorogenic substrate. The
assay measures the cleavage of AMC groups from a Caspase-3 specific substrate (AcDEVD-AMC) (Biomol Research Labs, Inc., plymouth Meeting, PA). Liberated AMC
groups were quantified on fluorometer at excitation max.: 365–380 nm and emission
max.: 430–460 nm. Briefly, cells were lysed in a protease inhibitor free lysis buffer
(50mM Tris, pH 8, 5mM EDTA, 150mM NaCl, 0.5% NP-40). The lysate was collected
by scraping. After clearing the lysate by centrifugation, protein was measured. 20 μg of
protein and 20 μM caspase-3 substrate were added into 50mM Tris, pH 7.5 reaction
buffer in triplicate in a 96-well plate. The reactions were incubated for 1h at 37oC and the
plate was read by a fluorometer, WALLAC Victor 1420 Multilabel counter with 355nm
excitation and 460nm emission filters (Perkin Elmer Life Sciences, Turku, Finland).
Assay for the chymotrypsin-like activity (CT-L) of the proteasome
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The (CT-L of the proteasome was measured using fluorogenic peptide substrate
as described elsewhere

20

. Briefly, 20μg of cell lysate protein was incubated with 20μM

of Suc-Leu-Leu-Val-AMC substrate for CT-L activity in 100μL of assay buffer (50mM
Tris-HCl, pH 7.6) for 1hr at 37oC. After incubation, production of 7-hydrolyzed 7amido-4-methyl-coumarin (AMC) groups were measured using WALLAC Victor 1420
Multilabel counter with 355nm excitation and 460nm emission filters (Perkin Elmer Life
Sciences, Turku, Finland).
Soft agar colony formation assay
After 48 hrs of siRNA treatment, the cells were trypsinized, counted and seeded at
a cell density of 2,000/well in triplicate in 12-well culture plates in 0.3% agar over a
0.6% bottom agar layer as previously described21. Cultures were incubated until colonies
formed (approximately 2-3 weeks). Plates were scanned after overnight incubation with 1
mg/ml

MTT

(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide,

Calbiochem), in cell growth medium. The colony numbers were visually determined and
quantified.
Cell invasion assay
Analysis of cell invasion was performed using artificial extracellular matrix
(Matrigel, 8uM pore size, BD Biosciences, Bedford, MA) according to the
manufacturer’s instructions. Briefly, the inserts were rehydrated by adding warm serumfree medium for 2 hrs at 37oC, 5% CO2 atmosphere. The medium was then removed from
the inserts, and 750ul of medium containing FBS was added to each well of the plate and
the inserts were placed on top of the medium. The transfected A549, Panc-1, and H460
(40,000 cells in 500ul of serum free-media) and HPNE cells (20,000) were added into the
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inserts. The cells were incubated for 48 hrs at 37oC. Cell invasion was determined by
staining the bottom parts of the insert with crystal violet (0.5% crystal violet in 25%
methanol). The porous membrane was removed and placed on the slide. The number of
cells that invaded were counted in three high-power microscope (40X) fields and
averaged as the mean number of invaded cells per field for each membrane.
Cell lines
The human cancer cell lines Calu-1, Panc-1, Hop-92 and Tov-21G, A549, SKOV3, ASPC-1, BxPC-3, and SW1990, H460 and Ovcar-5 were all obtained from ATCC but
none of the cell lines have been authenticated.
Results
Depletion of K-Ras decreases survivin levels in human cancer cells that harbor mutant,
but not wild type K-Ras.
Both mutant K-Ras and high levels of survivin contribute to malignant
transformation and are associated with poor cancer patient prognosis. However, whether
mutant K-Ras is required for the maintenance of high survivin levels is not known. To
address this important question we first depleted K-Ras from several human cancer cell
lines that either harbor mutant K-Ras or wild type Ras, and determined the effect of this
depletion on the levels of survivin.

Human cancer cell lines from various origins

including pancreatic (Panc-1, MiaPaca-2, SW1990, ASPC-1, BXPC-3), lung (A-549,
Calu-1, H460, HOP-92) and Ovarian (OVCAR5, SKOV-3), were transfected with nontargeting (NT) or K-Ras siRNA and processed for western blotting as described under
Materials and Methods. Figure 5A show that siRNA to K-Ras depleted K-Ras and that
this resulted in a significant decrease in the protein levels of survivin in cell lines that
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Figure 5. Depletion of K-Ras decreases survivin levels in human cancer
cells that harbor mutant K-Ras. A. Human cancer cell lines that harbor mutant
K-Ras (Panc-1, AsPC-1, A549, H460, MiaPaCa-2, Calu-1,SW1990) or wild type
Ras (BXPC3, HOP-92, Skov-3) were transfected either with non-targeting
siRNA (NT) or K-Ras siRNA and the cells were processed for western blot
analysis as described in Materials and Methods.

B. Panc-1 cells were

transfected with siRNA#2 that targets different regions of K-Ras mRNA and
processed for western blot analysis as described above. C. Depletion of K-Ras
reduces both exogenous and endogenous survivin. Panc-1 cells that stably
express either vector or MYC-DDK-Survivin were transfected with siRNA and
the cells were processed for western blot analysis as above. D. Panc-1 cells
were treated with siRNA for 36 hrs followed by VP-16 treatment for 24 hrs. Cells
were processed for western blot analysis as above. Data are representative of
at least two independent experiments.

harbor mutant K-Ras (Panc-1, Calu-1, H460, AsPC-1, MiaPaca-2, SW1990, A-549 and
OVCAR5) but not in those cancer cell lines that express only wild type Ras (BXPC3,
SKOV-3 and HOP-92).
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Next we used another K-Ras siRNA that target a different region of K-Ras
mRNA to confirm the results. Figures 5A and 5B show that depletion of K-Ras by two
distinct K-Ras siRNAs reduces survivin levels. Whether depleting K-Ras also reduces
the levels of ectopically expressed survivin was next investigated. To this end, cells were
stably transfected with Myc-DDK-tagged survivin and survivin protein levels were
determined following siRNA to NT or K-Ras transfection as described under Materials
and Methods. Figure 5C shows that depletion of K-Ras reduces the levels of endogenous
as well as exogenous survivin. The fact that depletion of K-Ras reduces the levels of
exogenous survivin, the expression of which was driven by a foreign promoter, suggests
that K-Ras may affect survivin levels by regulating its stability (see more below).
Depletion of K-Ras reduces the ability of VP16 to increase survivin levels.
Previous studies have shown that treatment with chemotherapeutic drugs such as
paclitaxel and VP16 results in survivin induction, and that this is an intrinsic mechanism
by which tumor cells develop resistance to chemotherapy. Since we found depletion of
K-Ras to decrease basal survivin protein levels, we reasoned that depletion of K-Ras may
also prevent induction of survivin by anticancer drugs in cancer cells that harbor mutant
K-Ras. Therefore, we next investigated whether the VP16- and paclitaxel mediated
increase in survivin levels requires mutant K-Ras.

To this end, Panc-1 cells were

transfected with siRNA to K-Ras or NT siRNA and treated with vehicle, VP16 or
paclitaxel and processed for western blotting as described under Materials and Methods.
Figures 5D and 5E show that in the absence of siRNA to K-Ras VP16 and paclitaxel
treatment of Panc-1 cells resulted in a robust increase in survivin levels. In contrast, in
Panc-1 cells where K-Ras was depleted, the ability of VP16 and paclitaxel to induce
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survivin was significantly compromised (Figures 5D and 5E). These results suggest that
K-Ras expression is required for the ability of VP16 and paclitaxel to increase survivin
protein levels, further confirming the role of mutant K-Ras in maintaining high levels of
survivin.
Ectopic expression of mutant K-Ras is not sufficient to induce survivin
Figure 5 demonstrated that depletion of K-Ras resulted in decreased levels of
endogenous and exogenous survivin as well as drug-induced survivin.

Next we

determined if ectopic expression of mutant, constitutive active K-Ras (CA-K-Ras),
increases survivin levels.
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Figure 6. Ectopic expression of CA-K-Ras is not sufficient to induce
survivin. HEK293 (A), NIH3T3 (B), HPNE (C) and C7 (D) cells that
stably express CA-K-Ras or vector were plated and grown for 48 hrs and
western blot analysis was performed to determine the survivin levels.

Human embryonic kidney HEK293 cells that ectopically express CA-K-Ras and
their parental counterpart that were transfected with an empty vector construct were used.
Figure 6A shows that forced expression of CA-K-Ras did not affect the protein levels of
survivin. Similar results were also obtained with NIH-3T3 cells as well as two primary
pancreatic ductal cell lines C7 and HPNE that stably express either CA-K-Ras or empty
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vector (Figures 6B, 6C and 6D), suggesting that K-Ras is not sufficient to drive the
expression of survivin. Taken together, the results from Figures 5 and 6 suggest that
mutant K-Ras is required but not sufficient for the maintenance of the high survivin
levels in human cancer cells.
Depletion of K-Ras decreases the stability of survivin by promoting its ubiquitination
and proteasome degradation.
Previous studies have shown that survivin protein undergoes proteasomal
degradation. To determine if depletion of K-Ras leads to decreased survivin protein
levels by inducing its proteasomal degradation, we used the proteasome inhibitor
bortezomib. First, we demonstrated that treatment of Panc-1 cells with bortezomib
resulted in the accumulation of survivin in a time-dependent manner starting as early as 1
hr and reaching a maximum at 4 hrs (Figure 7A). Next, whether bortezomib can rescue
from the K-Ras depletion-mediated decrease of survivin levels was investigated. To this
end, Panc-1 cells that stably express Myc-DDKtagged survivin were transfected with
either NT or K-Ras siRNA for 48 hrs prior to incubation with bortezomib for 1 hr and
processed the cells for western blotting as described under Materials and Methods.
Figure 7B shows that vector cells express only endogenous survivin whereas Mycsurvivin transfected cells express both endogenous and exogenous survivin (compare
lanes 1 and 2). In the absence of bortezomib, depleting K-Ras resulted in a significant
decrease of both endogenous and exogenous survivin levels (compare lanes 3 and 5). In
contrast, treatment of cells with bortezomib inhibited the ability of K-Ras siRNA to
decrease the levels of both endogenous and ectopically expressed survivin (compare
lanes 4 and 6 to lanes 3 and 5). Figure 7B also shows that bortezomib inhibited the CT-L
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activity of the proteasome by 83% and 88% in Panc-1 cells transfected with NT siRNA
and K-Ras siRNA, respectively.
We next determined whether K-Ras siRNA induces the degradation of survivin
by increasing its ubiquitination. To this end, survivin was immunoprecipitated from cells
that were transfected with siRNA to NT or K-Ras for 48 hrs followed by bortezomib
treatment as described under Materials and Methods. Figure 7C shows more
ubiquitinated survivin in the siRNA to K-Ras transfected cells. Thus, the results from
Figures 7B and 7C suggest that K-Ras depletion leads to ubiquitination and proteasomemediated degradation of survivin.
Phosphorylation of survivin at T34 has been shown to increase the stability of
survivin22, 23. One possible mechanism by which depletion of K-Ras could decrease the
stability of survivin is by inhibiting the phosphorylation of survivin at T34. We therefore
reasoned that the phospho mimic T34D survivin mutant should be resistant to K-Ras
depletion. To this end, we generated the T34D survivin mutant as well as the nonphosphorylatable T34A mutant. Panc-1 cells that stably express either wild type (WT),
T34D mutant or T34A mutant were transfected with siRNA to NT or K-Ras for 48 hrs
and the expression of survivin was followed by western blotting as described under
Materials and Methods.
Figure 7D shows that depletion of K-Ras reduces the expression of WT survivin
as well as T34A and T34D survivin mutants suggesting that the ability of K-Ras siRNA
to decrease survivin protein levels is not dependent on the phosphorylation status of
survivin at T34.
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A. Panc-1 cells were treated with the indicated dose of bortezomib for 1 hr. The
media was then replaced with drug-free media and the cells were allowed to grow
for the indicated length of time and processed for western blotting as described in
Materials and Methods. B. Panc-1 cells stably expressing Myc-DDK survivin were
treated with siRNA to NT or K-Ras, followed by vehicle or bortezomib treatment.
Cells were then harvested for western blot analysis or CT-L proteasome activity
assay as described in the Materials and Methods. C. A549 cells were transfected
with NT or K-Ras (K) siRNA for 48 hrs followed by bortezomib treatment for 30 min.
Survivin was immunoprecipitated and processed for western blot analysis for either
ubiquitin or survivin. D. Panc-1 cells that stably express vector, wt, T34A mutant or
T34D mutant survivin were transfected with NT or K-Ras siRNA and the cells
processed for western blotting as described in Materials and Methods. Data are
representative of at least two independent experiments.
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Depletion of K-Ras decreases selectively survivin over the anti-apoptotic proteins Bcl-2,
Bcl-XL and Mcl-1, and does not increase the levels of the pro-apoptotic proteins Bax
and Bad.
The ability of cancer cells to survive depends not only on IAP family members
but also on a balance between anti-apoptotic and pro-apoptotic Bcl-2 family members.
We therefore determined whether K-Ras depletion selectively affect survivin over other
proteins that regulate cancer cell survival. To this end, in addition to survivin, we
evaluated the effects of K-Ras depletion on anti-apoptotic (Bcl-2, Bcl-XL and Mcl-1) and
pro-apoptotic (Bad and Bax) proteins. Figure 8 (in the following page) shows that siRNA
to K-Ras decreased the levels of survivin but doesn’t affect the levels of the Bcl-2 family
proteins in Panc-1 and MiaPaca-2 cells.
Survivin is required for mutant K-Ras-driven malignant transformation
Both survivin and mutant K-Ras contribute to malignant transformation, but
whether survivin is required for K-Ras-driven malignant transformation is not known. In
an attempt to address this question, we next determined if depletion of survivin induces
apoptosis in HNPE cells where malignant transformation was induced by mutant K-Ras.
Figure 9 shows that depletion of survivin induces apoptosis in HPNE-K-Ras cells as
measured by caspase 3 activation and PARP cleavage, suggesting that survivin is a
critical protein that mediates at least in part the anti-apoptotic function of K-Ras. To
further confirm this result, we used different cell lines that harbor mutant K-Ras and
determined if depletion of survivin induces apoptosis. Our result shows that depletion of
survivin induces caspase 3 activation and PARP cleavage in A549 and H460 but not in
panc-1 cells.
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and XIAP were detected by western blot analysis. Data are representative of
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In addition to the well studied function of survivin in apoptosis, recent study have also
demonstrated that survivin contributes to invasion and metastasis and this role is
independent of its anti-apoptotic activity
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. The ability of cancer cells to grow in an

anchorage-independent manner is a prerequisite to metastasis. We therefore determined
if mutant K-Ras-induced colony formation in soft agar of HPNE pancreatic cells depends
on survivin. Figure 10 shows that HPNE cells transfected with vector grew 62 colonies
in soft agar. Transfection with mutant K-Ras enhanced the ability of HPNE cells to grow
soft agar colonies by 6.6-fold from 62 (vector cells) to 412 (K-Ras cells) colonies. Figure
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Figure 9. Depletion of survivin induce apoptosis in some cells. HPNE-K-Ras,
A549, Panc-1 and H460 cells were transfected with either control (NT) or survivin
siRNA for 96 hrs. Top panel: western blot analysis showing knockdown of survivin
and cleaved PARP and, bottom panel: caspase-3 activity following depletion of
survivin. Experiment was done in triplicates and error bars show SD deviation
between the triplicate wells. P value was calculated using the 3 values from the
triplicates and SD. Data are representative of two independent experiments.

10 shows that depletion of survivin potently inhibited this K-Ras-dependent increase in
colony formation in soft agar. This suggests that the ability of K-Ras to promote
anchorage- independent growth partly depends on survivin. Furthermore, the ability of
H-460 and Panc-1 cells, both of which harbor mutant K-Ras, to grow soft agar colonies
was also inhibited by depletion of survivin.
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While anchorage-independent growth is a pre-requisite for metastasis, another
close hallmark of metastasis is invasion. We therefore determined if mutant K-Ras-driven
invasion requires survivin. Figure 11 shows that mutant K-Ras increased the ability of
HPNE cells to invade by ~3.7-fold from 18 in vector cells to 67 in K-Ras transformed
cells. Figure 11 also shows that depletion of survivin inhibited the ability of K-Ras to
induce invasion. Similarly, in A-549, H-460 and Panc-1 cells, all of which harbor mutant
K-Ras, depletion of survivin significantly compromised their ability to invade (Figure
11).
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Discussion
The contributions of mutant K-Ras to several hallmarks of cancer including
deregulation of anchorage-dependent and –independent cell growth, invasion, metastasis
and apoptosis evasion have been well documented. In contrast, until recently, survivin
has only been well documented in preventing apoptosis and promoting mitosis. Recent
studies have demonstrated, as is the case for K-Ras, that survivin is also involved in other
65

hallmarks of cancer such as invasion and metastasis
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. However, little is known about

the regulation of survivin by mutant K-Ras and the contribution of survivin to mutant KRas-mediated malignant transformation.
In this manuscript, we used siRNA to knock down K-Ras expression in several
human cancer cell lines and demonstrated that depletion of K-Ras reduces survivin
protein levels in cancer cells that harbor mutant K-Ras but not wild type Ras. In addition
to decreasing the basal levels of survivin, depletion of K-Ras also inhibited the ability of
paclitaxel and VP-16 to induce survivin, further confirming the importance of K-Ras in
the maintenance of survivin. Furthermore, the K-Ras depletion- mediated reduction in
survivin levels was demonstrated in cancer cell lines from different tissue of origin.
Therefore, our results suggest that the requirement of K-Ras expression for the
maintenance of high levels of survivin in human cancer cells depends on the mutation
status of K-Ras but is not tissue specific.
Although our studies indicated that mutant K-Ras is required for the maintenance
of survivin, they also clearly demonstrated that mutant constitutively active (CA) K-Ras,
on its own, is not sufficient to induce survivin in several cell models including NIH-3T3
murine fibroblasts and human kidney embryonic HEK293 cells as well as 2 human
pancreatic cell lines C7 and HPNE. Whether ectopic expression of CA-H-Ras can
increase survivin levels is not clear with some studies showing that it can

14, 15

, and other

that it can not16. Consistent with our results, expression of CA-K-Ras in mouse kidneys in
the Wilm’s tumour mouse model was not able to induce survivin25. Interestingly, in this
model, expression of both CA-K-Ras and β-catenine was able to induce survivin25. This
study, coupled with our K-Ras depletion results, suggests that while several genetic
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aberrations are required for increasing the levels of survivin, depletion of only K-Ras is
able to decrease survivin. Therefore, K-Ras is necessary for the maintenance of survivin
but not sufficient to increase survivin levels.
In addition to depleting the endogenous levels of survivin, our studies also
demonstrated that depletion of K-Ras was able to decrease the levels of exogenous
survivin whose ectopic expression was under the control of a foreign promoter. This
suggested that depletion of K-Ras may affect the stability of the survivin protein, and this
was further confirmed by the demonstration that depletion of K-Ras increased survivin
ubiquitination, and that treatment with the proteasome inhibitor Bortezomib
compromised the ability of K-Ras siRNA to decrease the levels of the survivin protein.
Therefore, our studies indicate that depletion of K-Ras leads to decreased survivin levels
through a proteasome degradation mechanism. Survivin has a fairly short half-life of 30
min

26

, and its stability has been suggested to depend on phosphorylation of survivin at

T34 by CDK1

22, 23

.

We have made the phophomimic T34D as well as the non-

phosphorylatable T34A survivin mutants and have demonstrated that depletion of K-Ras
was as effective at decreasing the levels of these mutants as it was at decreasing the levels
of wild type survivin, suggesting that the ability of K-Ras depletion to promote the
proteasome degradation of survivin is independent of T34 phosphorylation. While these
results excludes the phosphorylation of survivin at T34 as the sole determinant of K-Ras
regulated survivin stability, it doesn’t rule out possible involvement of this
phosphorylation site in combination with other plausible K-Ras regulated mechanisms
that are involved in the stability of survivin.
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Depletion of K-Ras induces apoptosis in many human cancer cell lines that
depend on mutant K-Ras for survival 27, 28. However, whether this depends on the K-Ras
depletion-mediated decrease in survivin levels is not known. Using isogenic HCT-116
colon cell lines, Sarthy et al29 have found that survivin depletion induces apoptosis
preferentially in cancer cells that harbor mutant K-Ras. However, several studies using
RNAi screens have not all identified that depletion of survivin induces cell death in
cancer cells with K-Ras mutation27, 28. Consistent with this, our results also show that
mutation of K-Ras alone may not predict sensitivity to survivin depletion. For example,
depleting survivin in H460 and A549 but not in Panc-1 and MiaPaca 2 cells induces
apoptosis, yet all 4 cell lines harbor mutant K-Ras. Depletion of K-Ras may induce
apoptosis through other mechanisms, and this may include the decrease in the levels of
another IAP family member, XIAP, that we have observed in both Panc-1 and MiaPaca 2
cells following K-Ras depletion. However, apoptosis following depletion of K-Ras in
these 2 cell lines does not involve anti-apoptotic (Bcl-xL, Bcl-2 and Mcl-1) or proapoptotic (Bax and Bad) Bcl2 family members (Figure 8). Depletion of K-Ras may cause
global reduction in the levels of IAP family of proteins that may induce apoptosis. Future
studies that use a large number of cell lines that harbor mutant and wild type K-Ras are
warranted to identify the effect of survivin depletion in the context of K-Ras mutation.
Survivin has been associated with malignant transformation as its expression
increases at early stages of tumor development and its targeted expression in skin
predispose mice to UV induced tumors30. Our studies show that, mutant K-Ras also
depends on survivin for its ability to transform cells as well as to induce invasion. Using
a genetically-defined pancreatic cancer cell model, we have shown that the ability of
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mutant K-Ras to induce anchorage-independent cell growth on soft agar was inhibited by
depletion of survivin. Depletion of survivin also inhibited the anchorage-independent
growth of human cancer cells that harbor mutant K-Ras such as Panc-1 and H-460 cells.
Furthermore, the ability of mutant K-Ras to induce invasion in the genetically-defined
HPNE pancreatic cell model was also inhibited by depletion of survivin. The ability of A549, H-460 and Panc-1 cancer cells, all of which harbor mutant K-Ras, to invade was
also inhibited when survivin expression was knocked down. These results suggest that
survivin may be critical to the ability of mutant K-Ras to induce metastasis. This is
consistent with recent studies that implicated survivin in invasion and metastasis24.
Furthermore, the demonstration that depletion of survivin induce apoptosis in H460 and
A549 but not in panc-1 cells, and that its depletion antagonizes soft agar growth and
invasion in all three cell lines, suggests that the ability of survivin to regulate invasion or
soft agar growth is independent of its ability to regulate apoptosis.
In summary, this study identified an important biochemical link between the
protein product of one of the most frequently mutated gene in human cancer, K-Ras, and
the stability of a protein that is almost exclusively expressed in cancer, survivin; and that
this mutant K-Ras-survivin biochemical link contributes to K-Ras-driven malignant
transformation.
References
1.

Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell
144, 646-674 (2011).

2.

Salvesen, G.S. & Duckett, C.S. IAP proteins: blocking the road to death's door.
Nat Rev Mol Cell Biol 3, 401-410 (2002).

69

3.

Youle, R.J. & Strasser, A. The BCL-2 protein family: opposing activities that
mediate cell death. Nat Rev Mol Cell Biol 9, 47-59 (2008).

4.

Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin.
Nature 396, 580-584 (1998).

5.

Shin, S. et al. An anti-apoptotic protein human survivin is a direct inhibitor of
caspase-3 and -7. Biochemistry 40, 1117-1123 (2001).

6.

Lens, S.M., Vader, G. & Medema, R.H. The case for Survivin as mitotic
regulator. Curr Opin Cell Biol 18, 616-622 (2006).

7.

Lens, S.M. et al. Survivin is required for a sustained spindle checkpoint arrest in
response to lack of tension. EMBO J 22, 2934-2947 (2003).

8.

Chen, X.M. et al. Suppression of survivin expression by short hairpin RNA
induces apoptosis in human laryngeal carcinoma cells. ORL J Otorhinolaryngol
Relat Spec 70, 168-175 (2008).

9.

Li, C., Wu, Z., Liu, M., Pazgier, M. & Lu, W. Chemically synthesized human
survivin does not inhibit caspase-3. Protein Sci 17, 1624-1629 (2008).

10.

Dohi, T. et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 279, 3408734090 (2004).

11.

Ambrosini, G., Adida, C. & Altieri, D.C. A novel anti-apoptosis gene, survivin,
expressed in cancer and lymphoma. Nat Med 3, 917-921 (1997).

12.

Altieri, D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat
Rev Cancer 8, 61-70 (2008).

70

13.

Sommer, K.W., Schamberger, C.J., Schmidt, G.E., Sasgary, S. & Cerni, C.
Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-HRas. Oncogene 22, 4266-4280 (2003).

14.

Sommer, K.W. et al. Oncogenic c-H-ras deregulates survivin expression: an
improvement for survival. FEBS Lett 581, 4921-4926 (2007).

15.

Fukuda, S. & Pelus, L.M. Activated H-Ras regulates hematopoietic cell survival
by modulating Survivin. Biochem Biophys Res Commun 323, 636-644 (2004).

16.

Raj, D., Liu, T., Samadashwily, G., Li, F. & Grossman, D. Survivin repression by
p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 29, 194-201
(2008).

17.

Grossman, D. et al. Transgenic expression of survivin in keratinocytes
counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest
108, 991-999 (2001).

18.

Jin, Q., Menter, D.G., Mao, L., Hong, W.K. & Lee, H.Y. Survivin expression in
normal human bronchial epithelial cells: an early and critical step in
tumorigenesis induced by tobacco exposure. Carcinogenesis 29, 1614-1622
(2008).

19.

Lerner, E.C. et al. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is
highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase
and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene
15, 1283-1288 (1997).

20.

Kazi, A. et al. Discovery of a novel proteasome inhibitor selective for cancer cells
over non-transformed cells. Cell Cycle 8, 1940-1951 (2009).

71

21.

Falsetti, S.C. et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit
anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorageindependent growth. Mol Cell Biol 27, 8003-8014 (2007).

22.

O'Connor, D.S. et al. Regulation of apoptosis at cell division by p34cdc2
phosphorylation of survivin. Proc Natl Acad Sci U S A 97, 13103-13107 (2000).

23.

Wall, N.R., O'Connor, D.S., Plescia, J., Pommier, Y. & Altieri, D.C. Suppression
of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell
apoptosis. Cancer Res 63, 230-235 (2003).

24.

Mehrotra, S. et al. IAP regulation of metastasis. Cancer Cell 17, 53-64 (2010).

25.

Clark, P.E. et al. beta-Catenin and K-RAS synergize to form primitive renal
epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol 179,
3045-3055 (2011).

26.

Zhao, J., Tenev, T., Martins, L.M., Downward, J. & Lemoine, N.R. The ubiquitinproteasome pathway regulates survivin degradation in a cell cycle-dependent
manner. J Cell Sci 113 Pt 23, 4363-4371 (2000).

27.

Barbie, D.A. et al. Systematic RNA interference reveals that oncogenic KRASdriven cancers require TBK1. Nature 462, 108-112 (2009).

28.

Singh, A. et al. A gene expression signature associated with "K-Ras addiction"
reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500
(2009).

29.

Sarthy, A.V. et al. Survivin depletion preferentially reduces the survival of
activated K-Ras-transformed cells. Mol Cancer Ther 6, 269-276 (2007).

72

30.

Thomas, J. et al. Melanocyte expression of survivin promotes development and
metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res 67,
5172-5178 (2007).

73

Chapter 3

Requirement of Ral GTPases for survivin expression is mutation- but not tissuespecific

Abstract
Oncogenic K-Ras is known to induce malignant transformation by regulating
several proteins that are important for abnormal proliferation and survival. Although
previous studies have demonstrated the importance of survivin in Ras-mediated
malignant transformation, the downstream effectors critical for this regulation are less
studied. Here we show that, the small GTPase Ral, but not Akt or c-Raf, is critical for
survivin expression in cancer cells that harbor mutant K-Ras. Furthermore, we show that
Ral involvement in the regulation of survivin is mutation- but not -tissue specific. Indeed,
Ral regulation of survivin requires mutant K-Ras and wild type p53, and the ability of Ral
to regulate survivin depends on p53 that was induced following depletion of Ral. In
summary we have identified Ral as a novel regulator of survivin and that this regulation
is mutation- but not tissue-specific.
Keywords: K-Ras, Ral, survivin, p53, cancer,
Introduction
Ras is a member of the Ras super family of small GTPases that plays a critical
role in signal transduction1. There are three Ras genes that encode four 21KDa Ras
proteins, H-Ras, N-Ras, KA-Ras and KB-Ras. These signal transducers act as switches
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that are inactive when bound to GDP and active when bound to GTP. For example, in
normal cells when growth factors such as EGF bind their receptor, the receptors recruit
complexes that contain guanine nucleotide exchange factors (GEF) such as mSOS-1
which converts Ras-GDP (inactive) to Ras-GTP (active)2. In its GTP-bound active form
Ras can bind over 20 known effector proteins and trigger a multitude of signal
transduction pathways that are intimately involved in the regulation of cell division,
proliferation, differentiation and survival3.
Ras is mutated in about 30% of all human cancers. Mutation in amino acids 12,
13 or 614 are frequently observed and this results in a constitutively active (GTP-locked)
Ras that remains persistently activate and hence activates several down stream effectors
(see above).
This aberrant activation of Ras mediates many of the hallmarks of cancer
including uncontrolled cell division, sustained angiogenesis, metastasis and evasion of
apoptosis. The mechanisms by which mutant Ras contributes to these cancer hallmarks
has been extensively studied but much remains to be investigated.
Although Ras is known to engage over 20 effector proteins to regulate different
malignant phenotypes, the Raf/MAPK, Pi3K/Akt, RalGDS/Ral pathways have been
extensively studied: Ras binds and activates the kinase Raf which in turn activates Mek
to activate Erk5. This so-called MAP kinase cascade has been implicated in uncontrolled
proliferation of cancer cells. Ras also binds and activates phosphatidylinositol kinase
(Pi3K) which activates protein kinase B (Aka, Akt) which in turn triggers many pathways
involved in tumor survival, angiogenesis and metastasis6. Ras also bind the Ral GEF, Ral
GDS, which in turn activates the small GTPase, RalA and RalB7. Although early on the
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Raf/Mek/Erk and Pi3K/Akt pathways were implicated, more recently the Ral
GDS/RalA/B pathway has been shown to be just as important, and in some cases the only
mediator, of Ras driven malignant transformation8.
One of the major means by which mutant Ras causes malignant transformation of
human cancer is by inhibiting apoptosis and promoting tumor survival9. The mechanism
by which Ras inhibits apoptosis and hence maintains tumor survival is not well
understood. Several mediators have been proposed such as Bcl2, cyclin D1, NFkb and
others. More recently, the small IAP survivin has been shown to be induced by mutant
Ras and has been suggested as a mediator of Ras anti-apoptotic activity10. Moreover,
recently, we have found that depletion of K-Ras reduce survivin expression selectively in
cells that harbor mutant K-Ras20. However the mechanism by which mutant Ras increases
survivin levels is less known.
H-Ras has been shown to increase survivin levels in a dexamethasone-inducible
mutant CA-H-Ras system10. In this rat cell system, survivin expression was modulated
by the level of H-Ras expression. The induction of survivin expression by H-Ras was
cell cycle- and proliferation-independent. Furthermore, in Baf-3 cells, CA-H-Ras
increased survivin levels in the absence of IL-3, whereas DN Ras suppressed the IL-3stimulated survivin increase11. Similarly, in Hela cells CA-H-Ras induced sustained
survivin expression during all phases of the cell cycle, and protected against druginduced apoptosis12.
While the studies above suggested that H-Ras increased the levels of survivin and
that this increase contributes to the ability of Ras to protect cancer cells from apoptosis,
little is known about the mechanism by which Ras increases survivin levels.
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In

particular, the signal transduction pathways downstream of Ras that mediate the up
regulation of survivin are ill-understood. The few studies that attempted to address this
important question used only pharmacological inhibitors of Ras downstream effectors
(see Figure 12).

Figure 12. Inhibitors of Ras effecter pathways and survivin expression.
The Pi3K inhibitor (LY294002) and the MEK inhibitor (U0126) were shown to
reduce H-Ras driven survivin expression. The geranylgeranyl transferase
inhibitor (GGTI-2417) was shown to reduce survivin in a mutant K-Ras
harboring cells.

For example, one study showed that inhibitors of Mek, Pi3K and mTOR but not
Akt inhibited the ability of CA-H-Ras to increase the levels of survivin in BaF-3 cells11.
Similarly, in rat cells Mek and Pi3K inhibitors also inhibited CA-H-Ras-mediated
survivin increase and apoptosis10. However, in one study Pi3K inhibitors were unable to
inhibit survivin levels. Finally, we have shown that geranylgeranyl transferase I inhibitors
decreased the survivin levels in Mia-Pa-Ca-2 human pancreatic cancer cells, suggesting
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geranylgeranylated proteins such as RalA and RalB may be involved in the regulation of
survivin13, 14. The drawback of these studies is that they used pharmacological inhibitors
that may reduce survivin by off target effects. Moreover, the studies done so far
investigated the downstream effectors of ectopically expressed H-Ras not endogenous KRas.
In summary, only a few studies investigated the role of these canonical
downstream effectors in survivin expression that was induced by ectopic expression of HRas but the role of these effectors in cancer cells in the context of mutant K-Ras has not
been studied. Much investigation is needed to determine the mechanism by which Ras
maintains survivin levels.
Using different cancer cells from different tissue lineages and different genetical
backgrounds, we have found that RalA and /or RalB is involved in the regulation of
survivin expression only in cells with mutant K-Ras and wild-type p53 and the ability of
Ral to regulate survivin in mutant K-Ras harboring cells depends on p53.
Material and methods
Cell culture
Human tumor cell lines were grown in their respective media: A549 in Kaighn's
modification medium (F12K) (Gibco Laboratories, Grand Island, NY), Calu-1 and
SKOV-3 in McCoy’s 5a medium modified (Sigma-Aldrich, St. Louis, MO), H460,
AsPC-1, Ovcar-5 and BxPC-3 in RPMI, (Invitrogen, Carlsbad, CA), Panc-1, SW1990,
and HOP-92 in Dulbecco’s modified minimal essential medium (DMEM) (Invitrogen).
All cells were grown in their respective media containing 10% FBS and 1% penicillin/
streptomycin at 37oC in a humidified incubator at 5% CO2.
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siRNAs and antibodies
Non-targeting (NT), K-Ras, Raf-1, RalA and RalB siRNA were purchased from
Dharmacon, Lafayette, CO, Akt1/2 siRNA was obtained from Cell Signaling (Danvers,
MA) , respectively. Survivin antibodies were purchased from Abcam, Cambridge, MA
(used for western blotting). Akt1/2 and Raf-1 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Cleaved PARP antibody was purchased from Cell
Signaling (Danvers, MA). β-actin, vinculin and α-tubulin antibodies were purchased from
Sigma. K-Ras (OP-24), antibody was purchased from Calbiochem (Billerica, MA).
Peroxidase conjugated goat anti-mouse IgG, rabbit anti-goat IgG, mouse anti-rabbit IgG
antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove,
PA).
siRNA transfection
Cells were transfected with siRNA using Lipofectamine RNAiMAX transfection
reagent (Invitrogen) according to the manufacturer’s instructions. Briefly, cells were
plated overnight to reach ~40-50% confluence at the time of transfection. Lipofectamine
RNAiMAX and siRNAs were incubated with OptiMEM in separate tubes for 5 minutes,
then the diluted transfection reagent and siRNAs were mixed.

The mixture was

incubated at room temperature for 20 min. The siRNA/transfection reagent mixture was
then added drop-wise to the cells. After 24 hrs of transfection, growth media with 10%
serum only was added until the desired time of transfection.
Western blotting
Cells were rinsed with ice cold PBS twice and lysed on the plate using lysis buffer
containing 20mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
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100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium
orthovanadate, 1ug/mL leupeptin, and 1 mM PMSF. The lysate was harvested by
scraping and the debris was removed by centrifuging at 13000g for 13 min. The protein
content was measured using Bradford protein assay. Samples were resolved using 12.5%
SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA). The
membranes were blocked with 5% milk in TBST (Tris-Buffered Saline and Tween 20)
and then probed with the desired antibodies. The enhanced chemiluminescence blotting
system (PerkinElmer Inc, Waltham, MA) was used for antibody reaction.
Result
Depletion of Ral but not Raf or Akt reduces survivin expression in cancer cells with
mutant K-Ras.
We have previously found that mutant K-Ras is required for the maintenance of
high levels of survivin in cancer cells with mutant but not those with wild type K-Ras20.
However, the downstream effectors of Ras critical for this regulation are not known.
Although more than 20 downstream effectors of Ras are known so far, the RalGDS/Ral,
Pi3K/AKT, Raf/Mek/Erk pathways were extensively studied for their role in Ras-driven
signaling and malignant phenotypes. We therefore, determined which of the 3 pathways
mentioned above is involved in the regulation of survivin in the context of mutant K-Ras.
To this end, ovarian cancer cells that harbor mutant K-Ras (ovcar-5) and those that
harbor wild-type K-Ras (Skov-3) were transfected by siRNA to deplete K-Ras, RalA,
RalB, Akt, or c-Raf, and the effects of these depletions were determined by western
blotting as described under Methods. Figure 13 shows that depletion of RalA or K-Ras
reduces survivin in ovcar-5, whereas in in Skov-3 cells depletion of none of these genes
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reduced survivin levels. This suggests that RalA but not RalB, c-Raf or Akt1/2 is critical
for survivin expression in OVCAR-5 cells which harbor mutant K-Ras.
Skov-3

Ovcar-5
NT RalA RalB AKT Raf

NT

K-Ras

RalA

RalA

RalB

RalB

AKT1/2

Akt1/2

Raf

C-Raf1

K Ras

K-Ras

Survivin

Survivin

Actin

Actin

RalA RalB AKT1/2 Raf-1 K-Ras

Figure 13. Depletion of RalA but not RalB, Raf or Akt reduce survivin in
OVCA-5 cells which harbor mutant K-Ras. Ovcar-5 and Skov-3 cells were
transfected with the indicated siRNA for 48hrs and the cell lysates were
processed for western blotting where the membranes were probed with the
indicated antibody as described in the material and methods section.

Depletion of RalA or RalB fails to reduce survivin in pancreatic cancer cells.
Persistent activation of RalGTPases has been reported in many tumors where
mutations of K-Ras are prevalent. Since activated RalA and RalB are common in tumor
of pancreatic origin15, we determined if depletion of these genes could reduce survivin in
pancreatic cancer cells with and without mutant K-Ras. Our results (Figure 14) show that
while siRNA to K-Ras, reduced survivin levels, RalA or RalB failed to reduce survivin
levels in all human pancreatic cancer cells whether they harbor mutant or wild type KRas. Therefore, we conclude that the presence of mutant K-Ras alone is not sufficient to
predict if RalA or RalB can regulate survivin expression levels.
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Figure 14. Depletion of RalA or RalB fails to reduce survivin levels in pancreatic
cancer cells. The indicated pancreatic cancer cell lines were transfected with siRNA
to NT, RalA, RalB or K-Ras for 48hrs and then process for western blot analysis.

Depletion of RalA or RalB reduce survivin in subset of lung cancer cell lines
Since we observed that RalA can regulate survivin expression levels in ovcar-5
but not in any of the pancreatic cancer cell lines tested, we speculate that RalA
contribution in survivin expression could be tissue specific. To this end, we took lung
cancer cell lines with and without mutant K-Ras and investigate the effect of RalA or
RalB depletion on survivin expression. Our result (Figure 15) show that, while depletion
of RalA or RalB reduced survivin in H460 and A549 cells, depletion of Ral failed to
reduce survivin levels in a other human lung cancer cell lines such as Calu-1 as well as
those that harbor wt-K-Ras such as HOP-92.
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Figure 15. Depletion of K-Ras, RalA or RalB reduces survivin in subset of
lung cancer cell lines. Lung cancer cells with or without mutant K-Ras were
transfected with the indicated siRNA for western blot analysis and membrane were
probed with the indicated siRNA.

While in H460, A549 and Ovcar-5 depleting RalA and/or RalB reduced survivin
levels, in calu-1 and all the pancreatic cell lines we tested, depleting Ral had no
significant effect on survivin levels, yet all these cell lines harbor mutant K-Ras. Our
finding suggests that the regulation of the survivin expression levels by Ral proteins is
not tissue specific nor it is exclusively associated with the K-Ras mutation status of the
cells. This suggests that other factors may be involved in this regulation of survivin by
Ral. To this end, we looked at the mutation status of different genes to see if other
additional mutations can potentially affect the ability of Ral to regulate survivin
expression. Our analysis shows that, all cell line where we observe Ral involvement in
survivin expression, had in common mutant K-Ras and wild type p53 (see table 2). We
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therefore conclude that, in addition to the K-Ras mutation status of the cell, the p53 status
of a cells may determines the ability of Ral to regulate survivin.
Table 2. Mutation analysis revels that, involvement of Ral in survivin expression is
mutation- but not tissue-specific

Tissue
Lung
Lung
Lung
Lung
Ovary
Ovary
Ovary
Pancreas
pancreas
pancreas
pancreas

Cell line
A549
H460
Calu-1
Hop-92
SKOV-3
Ovcar-5
Tov-21G
MiaPaca-2
Panc-1
SW1990
BX-PC-3

Mutation status
K-ras
p53
MT
WT
MT
WT
MT
Deleted
WT
MT
WT
MT
MT
WT
MT
WT
MT
MT
MT
MT
MT
MT
WT
MT

Does depletion of
Ral affect survivin?
RalB
RalA
NO
NO
NO
RalA
RalA
NO
NO
NO
NO

The ability of Ral to regulate survivin depends on the presence of p53 and mutant KRas.
p53 is well known transcription factors that affect the expression of different gens
that are known to be involved in apoptosis and cell cycle regulation. Since previous
studies have shown negative regulation of survivin expression by wild-type p5316 and
lower survivin levels in tumors with wild-type p5317, we speculate that K-Ras or Ral
GTPases influence survivin expression in a p53-dependent manner. We therefore
hypothesize that, depletion of K-Ras or RalA or RalB may lead to increases in p53
expression levels and subsequently the induced p53 will interfere with survivin
expression. To determine if p53 plays a role in Ral regulated survivin, we co-deplete KRas, RalA or RalB with siRNA to p53 and ask if co-depletion of the genes rescue
survivin expression. For this, we took A549 cells that have mt-K-Ras and WT-p53 and
used siRNA to K-Ras, RalA or RalB alone or in combination with p53. Our result (Figure
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16) show that, while siRNA to K-Ras or RalB reduced survivin levels, co-depletion of KRas or RalB with p53 rescued from the reduction of survivin following K-Ras or RalB
depletion in A549 cells.

p53
NT K-Ras RalA RalB

NT

K-Ras RalA RalB

K-Ras
Survivin expression

RalA

Svv

Relative survivin
expression

RalB

1.20
1.00
0.80

Single siRNA

0.60

Plus p53 siRNA

0.40
0.20
0.00
NT

p53

K-Ras

RalA

RalB

siRNA

Actin

Figure 16. The ability of Ral to regulate survivin depends on p53 and on mutant
K-Ras. A549 cells were transfected either with siRNA to NT, K-Ras, RalA or RalB
alone or in combination with p53 for 48hrs and membrane was probed with the
indicated antibody. The graph on the right panel shows the normalized densitometry
values of p53 from the western blot in the left panel.

Discussion
The role of Ras in malignant transformation is well documented and the
contributions of different proteins in Ras-induced malignant transformation have been the
focus of intense scrutiny by different groups. To date, there are no FDA approved Ras
inhibitors in clinic and hence researchers have been working at identifying alternative
ways to disable Ras-driven malignant transformation. Some of these approaches include
identifying targets downstream of Ras that are drugable.
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Recently, we have demonstrated that K-Ras is required for the maintenance of the
high levels of survivin in human cancer cells that harbor mutant K-Ras but not in human
cancer cells where Ras is wild type20 and Chapter 2 of this thesis. These studies also
showed that depleting survivin reduces mutant K-Ras-driven anchorage-independent
growth and invasion. However, the K-Ras downstream effectors involved in survivin
regulation are not known. Here we investigated the role of three known downstream
effectors of Ras in the maintenance of high survivin levels in the context of mutant KRas. The Raf/Mek/Erk, Pi3K/Akt, and RalGDS/Ral pathways are three known canonical
downstream effectors that have been extensively studied with regards to their roles in
mediating Ras-driven malignant transformation. Although, initially the Raf/Mek/Erk and
Pi3K/Akt pathways were thought to be the most critical, more recently the RalGDS/Ral
pathway has been shown to be more important in mediating Ras-driven malignant
transformation in some cancer cells
To investigate the role of these three downstream pathways in regulating survivin
protein levels in the context of mutant K-Ras, we individually depleted c-Raf, Akt, RalA
and RalB by siRNA in two ovarian cancer cell lines, one that harbors mutant K-Ras
(ovcar-5) and the other that harbors wild type Ras (skov-3). Our study shows that
depleting K-Ras and RalA but not RalB, Akt, or c-Raf reduces survivin in ovcar-5 but not
in skov-3 cell line. Our study suggests that RalA but not the other downstream effectors
of Ras were critical to K-Ras regulation of survivin. Previous studies have used
pharmacological inhibitors to explore the role of Raf/Mek/Erk and Pi3K/Akt in survivin
expression10-12. The studies however show inconsistent findings when different cell lines
were used. While cell type differences remain a possible reason for these inconsistencies,
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it is also possible that off target effects from the drugs could explain these
inconsistencies. We therefore used a genetic approach, such as depletion of the genes by
siRNA to reduce off-target effect and to investigate the pathways of interest in a more
precise and defined pathway.
Persistently activated, GTP-bound Ral has been found in many tumors where
mutation of K-Ras is also prevalent15, 18. Since depletion of RalA reduces survivin in the
mutant K-Ras harboring ovarian cancer Ovcar-5 cells, we investigated the role of Ral in
human pancreatic cancer cells where previous studies show the presence of activated Ral.
Surprisingly, despite the presence of mutant K-Ras in these cancer cell lines, depletion of
RalA, RalB, Akt and c-Raf did not reduce survivin levels. These results suggest that the
involvement of Ral could be cell/tissue specific. Indeed previous studies have shown
differential role of Ral in cancers from different tissues of origin15,

18

. Although Ral

proteins share approximately 80% sequence identity overall, and 100% sequence identity
at their effector domains

19

, these small GTPases have been shown to bind to different

effectors and mediate different malignant phenotypes in different tissues. Lim et al have
shown that in pancreatic cancer RalA promote anchorage-independent growth and in vivo
tumor growth, RalB was shown to be involved in apoptosis and migration15. In colorectal
carcinoma however, while RalA promote similar phenotypes as in pancreatic cancer,
RalB actually antagonizes the effector RalA18. The differential effect observed in these
cell lines were partly due to their binding to different effectors. While RalA binds to Exo8 to promote the above-mentioned phenotypes, RalB binds to sec-5 to antagonize the
effect driven by RalA. We therefore speculated that Ral GTPase regulation of survivin
expression could be tissue specific. However, our depletion studies in several lung cancer
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cell lines argued against a tissue-specific effect. Indeed, depleting RalA and/or RalB
reduced survivin levels only in a subset of lung caner cell lines tested.
Consistently throughout our study, we have found that regardless of the tissue of
origin, depletion of Ral proteins fails to affect survivin levels in wt-K-Ras harboring
cancer cell lines. Interestingly, in this study we have also observed that despite the
differences in tissue of origin, depletion of RalA and/or RalB decreased survivin levels
only in cell lines that harbor mutant K-Ras. Furthermore, in pancreatic cancer cell lines
where p53 is mutated as well as in the lung cancer calu-1 cells where p53 is deleted,
depletion of RalA or RalB fails to reduce survivin levels. However, in other lung cancer
cell lines, H460 and A549, depletion of RalA and/or RalB reduces survivin levels. We
conclude that neither tissue of origin or mutation of K-Ras is sufficient to predict whether
depletion of Ral proteins will result in reduction of survivin levels, and that other factors
may be involved.
A closer look at the mutation status of these cell lines lead us to discover that
depletion of Ral proteins reduces survivin levels only in human cancer cell lines that
harbor mutant K-Ras and wild type p53, but not in those cell lines with wilt type K-Ras
and/or mutant p53. This observation is consistent with previous reports that showed that
WT but not mutant p53 regulates the expression of survivin. Our recently published
work demonstrated that depletion of K-Ras reduces survivin levels only in human cancer
cells that harbor mutant K-Ras, regardless of the mutation status of p53. Furthermore,
depletion of K-Ras in calu-1 cells where both p53 alleles are depleted reduced survivin
levels further supporting a p53-independent mechanism. However, in A-549 cells where
p53 is wild type, siRNA to p53 prevented the reduction in survivin following K-Ras
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depletion (see chapter 4 of this thesis), suggesting that K-Ras may regulate survivin in
p53 dependent and independent manner. Similar mode of regulation for the expression of
p21 has been demonstrated previously. While K-Ras appears to regulate survivin in p53dependent and -independent manner, Ral proteins seem to dependent on wild type p53
and mutant K-Ras to regulate Survivin. Consistent with this conclusion is the observation
that depleting Ral proteins failed to reduce survivin in all cell lines that harbor mutant
p53 despite the presence of mutant K-Ras. Similarly, Ral depletion failed to reduce
survivin levels in cell lines that express WT-K-Ras and WT-p53. More direct evidence
for the dependence on p53 comes from the observation that siRNA to p53 rescues from
survivin reduction following Ral depletion. We therefore conclude that Ral involvement
in the regulation of survivin depends on the mutation status of the cells and requires the
presence of mutant K-Ras and WT-p53.
In summary, our study used a large number of cell lines to investigate the
pathways downstream of K-Ras that are critical for the regulation of survivin expression
in the context of mutant K-Ras. Our study took advantage of using cancer cell lines that
harbor mutant K-Ras naturally instead of relying on artificial over expression that would
potentially cause stress on the cells and alter their normal behavior. Furthermore, our
studies lead to the discovery of the involvement of Ral GTPases, but not Akt or Raf, in
the regulation of survivin, a known protein that is involved in resistance to apoptosis and
promotion of cell cycle progression. An important finding of this work is the dependence
on mutant K-Ras and wild type p53 for the Ral regulation of survivin.
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Chapter 4

Ral GTPase down regulation stabilizes and reactivates p53 to inhibit malignant
transformation
Abstract
Ral GTPases are critical effectors of Ras, yet the molecular mechanism by which
they induce malignant transformation is not well understood. Here we show that down
regulation of K-Ras, RalA and RalB, but not Akt1/2 and c-Raf, leads to p53 Ser-15
phosphorylation and a significant increase in p53 half-life.

This increased stability

results in a p53-dependent up-regulation of p21waf and mdm2 and down-regulation of
survivin expression.

Furthermore, depletion of Ral GTPases inhibits cell cycle

progression, anchorage-independent growth and/or invasion in a p53-dependent manner.
Thus, expression of Ral proteins is critical to maintaining low levels of p53, and down
regulation of Ral GTPases reactivates p53 by significantly enhancing its stability, and
this contributes to suppression of malignant transformation.
Introduction
Malignant transformation is a complex process that involves constitutive
activation of proto-oncogenes and inactivation of tumor suppressor genes 1. The Ras
family members K-, N- and H-Ras are proto-oncogenes that are mutated and
constitutively activated in one third of all human cancers, with K-Ras mutations being the
most prevalent 2. Mutant Ras proteins induce malignant transformation by persistently
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activating several down stream pathways 3.

Among the most thoroughly studied

downstream effectors of Ras proteins are those mediated by the Raf/Mek/Erk, the
Pi3K/Akt, and the RalGDS/Ral pathways. These 3 pathways have been shown to be
required for Ras proteins to induce certain hallmarks of cancer such as uncontrolled
proliferation, apoptosis evasion, angiogenesis, migration and invasion 3. In addition to
activating pathways that promote oncogenesis, mutant Ras proteins also antagonize
tumor suppressive pathways to transform cells.
The tumor suppressor p53 is the genome guardian that prevents malignant
transformation by inducing cell cycle arrest, senescence and apoptosis in response to
stress signals such as oncogene activation 4, 5 and DNA damage 6, 7. p53 is a transcription
factor that induces or represses the expression of many genes including those involved in
cell cycle progression and cell survival

8

. Most human tumors contain non-functional

p53, either because of p53 mutations or inactivation of p53-dependent pathways 4, 9. One
mechanism by which tumors with wild type p53 inactivate it is by over expressing its
negative regulator mdm2, an E3 ligase that induces p53 degradation

10

. Another

mechanism by which wild type p53 is inactivated is by loss of the mdm2 antagonist ARF
11-13

. Therefore, for oncogenes to transform cells with wild type p53 they must trigger

pathways that lead to the inactivation of p53. In the case of the Ras proteins this is
isoform-dependent

14-17

. Cells challenged with mutant H-Ras or mutant N-Ras protect

them selves by inducing the expression of ARF
either by sequestering MDM2 in the nucleoli

18-20

13

which antagonizes MDM2 function

or by directly inhibiting its ubiquitin

ligase activity 11. This leads to increased p53 levels which in turn lead to senescence and
apoptosis 5. In contrast, mutant K-Ras suppresses p53
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16

but the mechanism involved is

not well understood. One proposed mechanism involves the activation of the E3 ligase
SNAIL which leads to ubiquitination of p53 and its proteasomal degradation16.
Although not thoroughly investigated, some studies reported on the regulation of
p53 by downstream effectors of Ras such as Raf and Akt but not Ral proteins. For
example, in Ras-transformed cells, Raf promotes the degradation of p53 by inducing
mdm2 and this leads to resistance to p53-dependent apoptosis following DNA damage21.
Furthermore, Akt phosphorylates mdm2 on S186 which leads to ubiquitination and
degradation of p53 22 . Whether Ral proteins regulate p53 and whether this contributes to
malignant transformation have not been investigated.
RalA and RalB GTPases are molecular switches that are on (active) when bound
to GTP and off (inactive) when bound to GDP

23

. RalGEFs such as RalGDS displace

GDP for GTP to activate Ral proteins 24. Ral proteins can be activated by Ras as well as
by other pathways that are independent of Ras

25, 26

. The interest in Ral proteins has

recently increased following the demonstration that in some cancers Ral proteins are
more critical than Raf and Akt in mediating Ras-driven malignant transformation

27

.

RalA and RalB share ~82% sequence identity, yet they have been shown to have
different contributions to malignant transformation processes, but this is cancer cell type
specific28-32.

For example, in pancreatic cancer cells, RalA promotes anchorage-

independent growth in soft agar and tumor growth in-vivo while RalB promotes cell
survival, invasion and migration29. In colon cancer cells, Ral A has similar functions as in
pancreatic cancer cells but RalB antagonizes RalA-driven anchorage-independent growth
30

. The reasons for these divergent effects are not known but differences in localization

32

and post- translational modifications 28, 31, 32 could be contributing factors.
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Although Ral proteins have been shown to induce many hallmarks of cancer such
as anchorage-dependent and -independent growth, migration and invasion33,

34

, the

molecular mechanism by which they accomplish this is not well understood. In addition,
whether Ral proteins antagonize tumor suppressive pathways to transform cell is not
known. For example, whether Ral proteins regulate the levels of the tumor suppressor
p53 and whether this contributes to their ability to induce malignant transformation are
not known. In this manuscript, we demonstrate that depletion of Ral proteins increases
p53 ser-15 phosphorylation and leads to a significant increase in p53 half-life and
stability. In addition, depletion of Ral proteins inhibits malignant transformation in a
p53-dependent manner. Taken together, these results suggest that down regulation of Ral
GTPases leads to stabilization and reactivation of p53 to inhibit malignant transformation
of cancer cells that harbor wt p53 and mt K-Ras.
Material and methods
Cell culture
The human tumor cell lines were grown in their respective media: H460, MCF-7,
Ovcar-5 and BxPC-3 in RPMI, (Invitrogen, Carlsbad, CA), A549 in Kaighn's
modification medium (F12K) (Sigma Aldrich, St. Louis, MO), Calu-1 in McCoy’s 5a
medium modified (Sigma-Aldrich, St. Louis, MO), Panc-1, HCT116 and HKH2 in
Dulbecco’s modified minimal essential medium (DMEM) (Invitrogen, Carlsbad, CA).
All cells were grown in their respective media containing 10% FBS and 1% penicillin
streptomycin at 37oC in a humidified incubator at 5% CO2.
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siRNAs and antibodies
Non-targeting (NT), K-Ras, RalA, RalB, p53 and p21, c-Raf siRNA were
purchased from Dharmacon (Lafayette, CO) and Akt 1,2,3 siRNA were purchased from
Cell Signaling (Danvers, MA).

Survivin antibody was purchased from Abcam

(Cambridge, MA). p21, c-Raf, p53 (DO-1), and Akt1/2 antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Cleaved PARP and phospho-p53 (Ser-15)
antibodies were purchased from Cell Signaling. RalB and MDM2 antibody was
purchased from Millipore (Billerica, MA). β-actin, vinculin, α-tubulin and GAPDH
antibodies were purchased from Sigma-Aldrich. K-Ras (OP-24) antibody was purchased
from Calbiochem (Billerica, MA). RalA antibody was purchased from BD Biosciences,
(Bedford, MA), Peroxidase-conjugated rabbit anti-goat IgG, goat anti-mouse IgG, and
mouse anti-rabbit IgG antibodies were purchased from Jackson ImmunoResearch
Laboratories (West Grove, PA).
siRNA transfection
All cells used in this manuscript were transfected with a similar siRNA
transfection protocol using Lipofectamine RNAiMAX transfection reagent (Invitrogen,
Carlsbad, CA). The cells were plated overnight to reach ~40-50% confluence at the time
of transfection. Opti-MEM reduced serum medium (Invitrogen) and Lipofectamine
RNAiMAX were mixed in one tube and a mixture of Opti-MEM and siRNA was
prepared in a separate tube, and the content of the two tubes were mixed after 5 minutes
of incubation at room temperature. Following this, the mixture was incubated for 20
minutes at room temperature and then added to the cells drop-wise. After 24 hours of
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transfection, appropriate media with 10% serum only was added until the desired time of
transfection.
DNA transfection
Cells were plated overnight to reach 70-80% confluence and transfected with
DNA using Lipofectamine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s instructions. Briefly, Lipofectamine 2000 reagent (1.5μl/μg of DNA) was
diluted in Opti-MEM and allowed to equilibrate for 5 minutes at room temperature. DNA
was diluted in Opti-MEM in a separate tube. The contents of the two tubes were mixed
and incubated for 20 minutes to complex at room temperature, then added drop wise to
cells that contain only 10% FBS containing regular growth media. The cells were
transfected for 6 hours before changing the medium to 10% FBS only regular growth
media.
Western blotting
Cells were rinsed with ice-cold PBS twice and lysed on the plate in lysis buffer
containing 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium
orthovanadate, 1µg/mL leupeptin, and 1 mM PMSF. The lysate was collected by scraping
and centrifuging at 13000xg for 13 minutes to remove the debris. The protein content was
measured using Bradford protein assay. Samples were resolved using SDS-PAGE and
transferred to PVDF membranes (Millipore). The membranes were blocked with 5% milk
in Tris-buffered saline and Tween-20 (TBST) and then probed with the desired
antibodies. Western Lightning ECL (PerkinElmer Inc, Waltham, MA) was used for
antibody detection.
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Caspase activation assay
Caspase-3 activity was measured in cell lysates using a fluorogenic substrate. The
assay measures the cleavage of AMC groups from a Caspase-3 specific substrate (AcDEVD-AMC) (Biomol Research Labs, Inc., Plymouth Meeting, PA). Briefly, cells were
lysed in a protease inhibitor-free lysis buffer (50 mM Tris, pH 8, 5 mM EDTA, 150 mM
NaCl, and 0.5% Igepal). The lysate was collected by scraping. After clearing the lysate
by centrifugation, protein was measured. 20 μg of protein and 20 μM caspase-3 substrate
were added into 50 mM Tris, pH 7.5 reaction buffer in triplicate in a 96-well plate. The
reactions were incubated for 1 hour at 37oC and liberated AMC groups were quantified
by a fluorometer (WALLAC Victor 1420 Multilabel counter, Perkin Elmer Life Sciences,
Turku, Finland) with 355 nm excitation and 460 nm emission filters.
Soft agar colony formation assay
A549 and H460 cells were transfected with siRNA for 48 hours, then the cells
were trypsinized, counted and 2,000 cells/well were seeded in triplicate in 12-well culture
plates in 0.3% top agar over 0.6% bottom agar layer as previously described. Cultures
were incubated for two weeks (H460) or three weeks (HCT116). Plates were scanned
after overnight incubation with 2 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide, Calbiochem), in phosphate buffered saline. The colony
numbers were visually determined and quantified.
Cell invasion assay
Analysis of cell invasion was performed using 24-well Matrigel invasion
chambers (8 µM pore size, BD Biosciences, Bedford, MA) according to the
manufacturer’s instructions. Briefly, the inserts were rehydrated by adding warm serum-
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free medium for 2 hours at 37oC, 5% CO2 atmosphere. The medium was then removed
from the inserts, and 750 µl of medium containing 20%FBS was added to each well of
the plate and the inserts were placed on top of the medium. Transfected A549, Panc-1,
and H460 (40,000 cells in 500 µl of serum free-media) and HPNE cells (20,000 cells)
were added to the inserts. The cells were incubated for 48 hours at 37oC. Cell invasion
was determined by staining the bottom of the insert with crystal violet (0.5% crystal
violet in 25% methanol). The porous membrane was removed and placed on the slide.
The number of cells that invaded were counted in three high-power microscope (40X)
fields and averaged as the mean number of invaded cells per field for each membrane.
Promoter-reporter transcriptional assay
To determine the effect of K-Ras, RalA or RalB depletion on p21 promoter
activity, 300,000 H460 or A549 cells were plated overnight, in triplicate, in 6-well plates
followed by 3 μg of p21 and (1:50 b-gal) transfection using Lipofectamine 2000 (as
described above). 12hrs after DNA transfection, the cells were then transfected with
different siRNAs using Lipofectamine RNAiMax or using Lipofectamine 2000 as
described above. Following 48 hours of siRNA or DNA transfection, cells were rinsed
with PBS and then lysed on the plate using Reporter Lysis Buffer (RLB) as described by
the manufacturer (Promega BioScience, San Luis Obispo, CA). Cells were then freezethawed for efficient lysis. The lysate was centrifuged at 12,000g for 2 minutes to remove
debris. The p21 promoter activity was detected by incubating the lysate with the assay
substrate. The luciferase activity was detected using a TD-20/20 luminometer (Turner
Designs, Sunnyvale, CA) and b-galactosidase was read at 420nm wave lenght using Biot-

100

Tek plate reader The p21 promoter activity was normalized to the respective bgalactosidase reading.
Determination of p53 half-life
H460 or A549 cells were transfected with siRNA. Following 48 hours of
transfection, cells were treated with 50 µg/mL of cyclohexamide for 0, 0.5, 1, 2, or 4
hours and then harvested and processed for western blot analysis as indicated above.
Cell cycle analysis
A549 cells were transfected with different siRNAs for 48 hours. Following
completion of siRNA transfection, cells were trypsinized and then centrifuged at 200xg
for 5 minutes to harvest the cells. The cells were then rinsed with PBS twice and then resuspended in ethanol overnight. Following overnight fixation, cells were then
centrifuged. The supernatant was removed and rinsed with PBS. The cells were stained
with propidium (PI) iodide stain that contain 20ug/mL PI, 0.1%(v/v) Triton in PBS and
0.2mg/mL DNAase free RNAase A for 2 hours at room temperature. Cells distribution on
different cell cycle phase was determined using a flow cytometer.
Cell lines
The human cancer cell lines Calu-1, Panc-1, A549, BxPC-3, H460, HCT116,
MCF-7 and Ovcar-5 were all obtained from ATCC but none of the cell lines have been
authenticated.
Results
Expression of K-Ras, RalA or RalB, but not AKT1/2 or c-Raf, is required for
the maintenance of low levels of p53 in human cancer cells that harbor mutant K-Ras
and wild type p53
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About half of human cancers lack the tumor suppressive activity of p53 due to
gene deletions or mutations9, 35-38 . The other half that express wild type (wt) p53 harbor
aberrant pathways that either inactivate p53 or suppress its expression levels

9, 35-38

.

Mutant (mt) K-Ras is known to down regulate wt p53 levels but little is known about the
contributions of its down stream effectors.

For example, Ral GTPases are critical

mediators of K-Ras-driven malignant transformation but whether they regulate wt p53 is
not known. To address this important question, we first determined whether depletion of
Ral GTPases affects the expression levels of p53 in A549 and H460 cell lines that harbor
mt K-Ras and wt-p53.

Since Akt and Raf are also critical to Ras malignant

transformation, we also investigated the effects of their depletion on the expression levels
of p53. To this end, A549 and H460 cells were transfected with either non-targeting
siRNA or siRNAs to K-Ras, RalA, RalB, AKT1/2 or c-Raf and the cells were processed
for western blotting as described under Experimental Procedures. Figure 17 shows that in
both A549 and H460 cells depletion of K-Ras, but not Akt1/2 and c-Raf, resulted in
increased p53 levels. Depletion of RalB in both cell lines also increased p53 and this
increase was more pronounced (3.5-fold for both A549 and H460) than with K-Ras
depletion (1.6 (H460) and 2.4 (A549)-fold). Furthermore, depletion of RalA increased
the levels of p53 in H460 but had little effect in A549 (Figure 17). To determine if the
increase in p53 levels is dependent on the mutation status of K-Ras and p53, we used
other cell lines with mt K-Ras and wt p53 (HCT116 colon cancer cells and OVCAR5
ovarian cancer cells), wt K-Ras and wt p53 (MCF7 breast cancer cells and HCT116 cells
where the mutant K-Ras was deleted by homologous recombination (HKH2 cells), wt KRas and mt p53 (BXPC3 pancreatic cancer cells), and mt K-Ras and mt p53 (Panc1
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pancreatic cancer cells). Figure 18 shows that depletion of K-Ras, RalA and RalB
increased p53 levels in cells with mt K-Ras and wt p53 (HCT116 and OVCAR5) but
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Figure 17. Depletion of RalA and/or Ral B increases p53 protein
levels in cancer cells with WT-p53 and mt-K-Ras. A. Depletion of RalA
and/or Ral B but not AKT1/2 or c-Raf affects p53 expression in cells with
mt-K-Ras and wt-p53. H460 and A549 cells were transfected with the
indicated siRNA for 48hrs and processed for western blotting analysis as
described in the material and method section.

not in cells with either wt K-Ras and/or mt p53 (MCF7, BXPC3 and Panc1).
Furthermore, depletion of K-Ras, RalA and RalB in the isogenic cell line HCT-116
(HKH-2) where the mutant K-Ras allele was deleted had little effect on the levels of p53
(Figure 18). Therefore, our results suggest that in human cancer cells that harbor mt KRas and wt p53, the expression of K-Ras, RalA and/or RalB is required for the
maintenance of low levels of p53.
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Figure 18. Depletion of K-Ras, RalA or RalB increase p53 expression
selectively in cells with mutant K-Ras and wild-type p53. Cancer cells that
harbor mt K-Ras and wt p53 (HCT116 colon cancer cells and OVCAR5
ovarian cancer cells), wt K-Ras and wt p53 (HKH2, MCF7 breast cancer
cells), wt K-Ras and mt p53 (BXPC3 pancreatic cancer cells) and mt K-Ras
and mt p53 (Panc1 pancreatic cancer cells) were transfected with the
indicated siRNA for 48hrs and processed for western blotting analysis as
described in the Experimental Procedures section. Data are representative of
three (A549, H460 and HCT116) or two (Ovcar-5, panc-1, HKH2, MCF-7 and
BxPC-3) independent experiments. (N, K, A and B designate Non targeting,
K-Ras, RalA and RalB siRNA, respectively).

Depletion of K-Ras, RalA and RalB leads to up-regulation of p21 and down-regulation
of survivin expression in a p53-dependent manner
p53 controls cell cycle progression and cell survival by regulating at the
transcriptional levels the expression of several genes that are involved in cell cycle
progression (e.g. p21) as well as those involved in apoptosis (e.g. survivin)

39-42

.

Therefore, we next determined whether Ral GTPases are involved in the regulation of
these genes and whether this is dependent on p53. Figure 19A shows that in A-549 cells,
depletion of K-Ras and RalB increased the protein levels of p53 and p21. Consistent
with this, depletion of K-Ras and RalB also increased the p21 promoter transcriptional
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experiments that were done twice
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activity (Figure 19B). Furthermore, Figure 19A also shows that depletion of K-Ras and
RalB decreased the levels of survivin. In H460 cells, depletion of K-Ras, RalA and RalB
increased p21 expression at the protein (Figure 19C) as well as the transcriptional (Figure
19D) levels. We next determined whether this increase in p21 and decrease in survivin
levels are dependent on the expression of p53. To this end, we took two approaches.
First, since depleting K-Ras, RalA and RalB increased p53 levels, we reasoned that codepleting p53 should rescue if the effects are p53-dependent. Therefore, we transfected
A549 and H460 cells with K-Ras, RalA or RalB siRNAs alone or in combination with
p53 siRNA and evaluated the levels of p53, p21 and survivin as described under
Experimental Procedures.

Figures 19A and 19C show that K-Ras, RalA and RalB

siRNAs were unable to decrease survivin and/or increase p21 protein levels in the
absence of p53. Similar results were obtained with p21 promoter transcriptional activity
(Figures 19B and 19D). In the second approach we used a cell line where K-Ras is
mutated and both p53 alleles are deleted (human lung cancer calu-1 cells) and determined
the effects of depleting K-Ras, RalA and RalB. Figure 19E shows that depletion of RalA
and RalB failed to increase p21 and to decrease survivin expression levels. In contrast,
depletion of K-Ras decreased the levels of survivin but was unable to increase the levels
of p21, suggesting that in calu-1 cells the ability of K-Ras to regulate p21 but not survivin
is p53-dependent.
Depletion of RalA and RalB increases p53 Ser-15 phosphorylation and p53 stability
and half life
Figures 17,18 and 19 demonstrated that depletion of Ral GTPases increased the
amount of functional p53 protein in human cancer cells with mt K-Ras and wt p53, and

106

that this resulted in the modulation of p53-regulated genes such as p21 and survivin. We
next determined whether the increase in p53 levels is due to increased stability of the p53
protein. To this end, H460 cells were transfected with either non-targeting (NT) siRNA
or siRNA to K-Ras, RalA or RalB for 48 hours followed by treatment with
cyclohexamide (CHX) for 0, 0.5, 1, 2 or 4 hrs and the cells processed for western blotting
as described under Experimental Procedures. Figure 20 and Figure 21 show that in cells
transfected with NT siRNA, the protein levels of p53 decreased steadily after treatment
with CHX with a half-life between 30 and 60 minutes.
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Figure 20. Depletion of K-Ras, RalA and RalB increases p53 protein stability.
H460 cells were treated with non targeting, K-Ras, RalA or Ral B siRNA for 48 hrs
followed by cyclohexamide treatment for the indicated lengths of time. Cells were
harvested and processed for western blotting analysis as described in the
Experimental Procedures section. Data are representative of two independent
experiments.
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In cells transfected with RalA, RalB or K-Ras siRNA,

p53 protein levels

decreased after CHX treatment but at a much slower rate with half-lives greater than 4
hrs (RalA and RalB siRNAs) and greater than 2 hrs (K-Ras siRNA) (Figure 20 and
Figure 21). Thus, in the absence of RalA and RalB, p53 half-life was increased by
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108

greater than 6 fold and in the absence of K-Ras it was increased by greater than 2 fold.
Similar results were obtained in A-549 cells where RalB depletion also increased the
half-life of p53 from 30 min to 4 hours Figure 22. Depletion of K-Ras, RalA and RalB
also increased the levels of mdm2, but in contrast to p53,
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Figure 22. Depletion of RalB increases p53 stability in A549 cells. A.
A549 cells were transfected with the indicated siRNA for 48hrs followed by
cyclohexamide treatment for the indicated length of time and processed for
western blot analysis as indicated in the material and method section. B.
p53 and mdm2 from (A) were quantified as described under Figure 1S
legend. C. A549 cells were transfected with the indicated siRNA for 48hrs
and then processed for WB analysis.

Data are representative of 3

independent experiments.

it had little effect on its half-life (about 30 min with and without K-Ras, RalA and RalB
siRNAs). This suggests that depletion of K-Ras, RalA or RalB stabilizes p53 which in
turn induces the expression of mdm2, a known target for p53. Consistent with this, the
ability of RalB siRNA to increase mdm2 levels was rescued by p53 siRNA suggesting
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that RalB depletion up-regulates mdm2 expression in a p53-dependent manner Figure
22). Phosphorylation of p53 at ser-15 has been extensively used as a marker for stability
of p53

43, 44

. Therefore we next determined the effects of RalA, RalB and K-Ras

depletions on p53 Ser-15 phosphorylation. Figure 20 shows that deletion of RalA and
RalB in H460 cells resulted in increased p53 Ser-15 phosphorylation. Similar results
were seen with A549 cells where depletion of RalB also increased p53 Ser15
phosphorylation, Figure 22.
Depletion of RalB inhibits cell cycle progression in a p53- and p21-dependent manner
by decreasing the proportion of cells in S phase
Cells exposed to DNA-damaging agents induce p53 which in turn induces,
depending on the extent of the damage, either cell cycle arrest or apoptosis by regulating
the transcription of specific genes

39-42

. Since p53 was induced and up-regulated p21

expression following depletion of RalA, RalB or K-Ras, we next determined whether this
increase in p53 has functional consequences on cell cycle progression. To this end, we
transfected A549 cells with siRNA to K-Ras, RalA or RalB and processed the cells for
cell cycle analysis as described under Experimental Procedures. Figures 23 show that
depletion of RalA had little effect on cell cycle progression. In contrast, depletion of
RalB decreased the percentage of cells in S-phase by 57% (Figure 23 and Table 3A) to 70
% (Figure 23 and Table 3A) whereas K-Ras increased the percentage of cells in G2M
phase by 4 to 6.7 fold (Figures 23/ Table 3A ). To determine if these effects are p53dependent, we co-transfected the cells with siRNA to p53 along with siRNAs to either KRas, RalA or RalB and determined the effects on cell cycle progression as described
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under Experimental Procedures. Figure 23 and Table 3A show that depletion of p53
inhibited RalB and K-Ras siRNAs from affecting cell cycle progression.
Since p21 is known to be up-regulated by p53 and to be involved in G1/S
transition, we next determined if the p21 induction by p53 following depletion of RalB is
required for RalB siRNA to decrease the percentage of cells in S phase. To this end, we
co-transfected the cells with
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Figure 23. Effects of Depletion of K-Ras, RalA and Ral B on cell cycle
progression. A549 cells were treated with the indicated siRNA for 48 hrs and
processed for cell cycle analysis as described in the Experimental Procedures
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(A) Depletion of P53 rescue. (B) Depletion of p21 rescue.

111

siRNA to p21 along with siRNAs to either K-Ras, RalA or RalB and determined the
effects on cell cycle progression as described under Experimental Procedures. Figure 23
and Table 3B shows that, co-depletion of p21 completely rescued from the effects of
RalB siRNA on cell cycle progression suggesting that the ability of RalB siRNA to
decrease the proportion of cells in S phase depends on p53-induced p21.
Table 3. Percent of cells at different phases of cell cycle.

Table 3A. Cell cycle distribution

Table 3B. Cell cycle distribution
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Effects of Depleting RalA and RalB on apoptosis
As mentioned above another important function of p53 is to promote apoptosis.
Furthermore, depletion of RalB but not RalA has been shown to induce apoptosis
the molecular mechanism by which this occurs is not known.

33

but

Therefore, we next

determined whether depletion of RalB induces apoptosis and whether this is p53dependent. To this end, we transfected A549 and H460 cells with siRNA to K-Ras, RalA
or RalB in the presence or absence of siRNA to p53 and processed the cells for western
blotting and for Caspase 3 activation by a fluorescence assay as described under
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Experimental Procedures. Figure 24 shows that in A549 cells, depletion of K-Ras and
RalB but not RalA induced apoptosis with K-Ras depletion having significantly higher
effects (7-fold from 200 to 1400) than RalB depletion (3-fold from 200 to 600). Figure
24 also shows that siRNA to p53 inhibited K-Ras and RalB siRNA from inducing
apoptosis. These results suggest that depletion of K-Ras and RalB induced apoptosis by
a p53-dependent mechanism in A549 cells. In H460 cells, however, depletion of K-Ras
but not that of RalA and RalB significantly induces apoptosis Figure 24, and depletion of
p53 rescues apoptosis.
Depletion of RalB and to a lesser extent RalA inhibits anchorage-independent growth
and invasion in a p53-dependent manner
The involvement of RalA and RalB in malignant transformation has been well
documented

45

.

While RalA is believed to be involved in promoting anchorage-

independent growth in soft agar, RalB is believed to promote invasion and migration,
although this is cell type-dependent28-32. Since p53 is a potent tumor suppressor, we
reasoned that Ral proteins may affect some of these hallmarks of transformation in a p53dependent manner. To this end we depleted K-Ras, RalA or RalB in the presence or
absence of p53 siRNA and processed the cells for soft agar and invasion assays as
described under Experimental Procedures. Figure 25 shows that depleting K-Ras or RalB
but not RalA inhibited soft agar growth of H460 and HCT116 cells. The inhibition of
soft agar growth following RalB depletion was rescued fully by siRNA to p53. In
contrast, siRNA to p53 only partially rescued from the inhibition of soft agar growth
following K-Ras depletion. Another critical hallmark of cancer is invasion; we therefore
investigated the effects of depleting these 3 proteins on invasion. Figure 26 shows that
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depletion of K-Ras, RalB and to a lesser extent RalA inhibited invasion of all 3 cell lines,
A549, HCT116 and H460. Co-depletion with p53 rescued from this inhibition of invasion
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Figure 24. Effects of depleting K-Ras, RalA and RalB on apoptosis. H460
and A549 cells were transfected with siRNA for 48 hrs and then harvested for
western blot analysis (left panel) or caspase-3 activation assay (right panel) as
described under Experimental Procedures. Data are representative of 2
independent experiments.

These results suggest that depletion of K-Ras, RalA and RalB requires p53 to inhibit
invasion of A549, H460 and HCT116 cells.
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Figure 25. Effects of Depletion of K-Ras, Ral A and Ral B on anchorageindependent growth. H460 or HCT116 cells were transfected with the
indicated siRNA for 48hrs before plating in soft agar as described in
Experimental Procedures section. Results are shown as average % inhibition of
four independent experiments (H460) or three independent experiments
(HCT116). NT and NT+p53 siRNA were set as 100%. For H460 Mean number
of colonies for NT was 323+/-8.5 and for NT+p53 siRNA was 232+/-66.22; and
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siRNA was 484 +/- 6. Error bars show SE. Student t-test was used to compare
the means; and p-values are shown for tests that show significant differences (*,
p<0.05). Top panel shows representative soft agar pictures for HCT116 cells
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Figure 26. Effects of Depletion of K-Ras, Ral A and Ral B on invasion.
A549, H460 or HCT116 cells were transfected with the indicated siRNA for 48
hrs, then equal number of cells were seeded for invasion assays as described in
the material and method section. The cells were then photographed and counted
to determine the mean number of invading cells. Top panel shows
representative image of invading cells of H460, while bottom panels show
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P values for HCT116 are K-Ras 0.006, RalB 0.007. P values for

A549 are K-Ras 0.004 and RalB 0.0006)

Discussion
Among the three most studied downstream effector pathways of Ras,
Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral, recently the latter has gained more attention as
it has been shown to be more critical in mediating Ras-driven malignant transformation
116

in several cancers 27, 46. Specifically RalA has been implicated in anchorage-independent
growth whereas RalB has been implicated in apoptosis evasion, migration and invasion,
although this is cell-type-dependent

28-32, 39

. The mechanism by which RalA and RalB

mediate these effects is not well understood. Furthermore, mt K-Ras suppresses p53
levels but it is not known which of its downstream effectors mediate this effect. In this
manuscript we have demonstrated that the expression of K-Ras, RalA and RalB but not cRaf and Akt1/2 is required for maintaining low levels of p53 in human cancer cells that
harbor mt K-Ras and wt p53. The observation that depletion of K-Ras increased p53
levels is novel and consistent with observation that K-Ras can suppress p53 levels

16

.

Indeed, while mt H-Ras and mt N-Ras were shown to induce p53 levels and senescence,
mt K-Ras was shown to suppress p53 levels 11, 14, 16-20. Therefore, it is not surprising that,
unlike cells that harbor mt H-Ras and mt N-Ras, many human cancer cells that harbor mt
K-Ras also express wt p53, suggesting that mt K-Ras triggers pathways capable of
overcoming the tumor suppressive activity of p53. Our studies suggest that RalA and
RalB could be among those pathways that may be used by mt K-Ras to suppress p53
levels. In contrast, pathways mediated by c-Raf and Akt1/2 do not appear to be required
since their depletion did not increase p53 levels. While our studies demonstrated that
depletion of Raf or Akt does not increase p53 levels, others have shown that forced
expression of Raf or Akt induces p53 degradation21, 22. This suggests that while Raf and
Akt can induce degradation of p53, their expression is not required to maintain low levels
of p53 in some human cancer cells. It is important to note that depletion of RalA and
RalB increased p53 levels only in human cancers cells that harbor mt K-Ras and wt p53,
suggesting that RalA and RalB may mediate the ability of mt K-Ras to suppress p53.
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However, the fact that depletion of RalB was more potent at increasing the levels of p53
than depletion of K-Ras (Figure 19) coupled with the fact that depletion of RalB and KRas affected cell cycle progression differently (Figure 23) suggest that RalB may also
regulate p53 in a K-Ras-independent manner.
In addition to increasing p53 levels, depletion of RalA and RalB also increased
the expression levels of p21 and mdm2 and decreased the expression levels of survivin,
all 3 genes known to be transcriptionally-regulated by p53. The p53 siRNA rescue from
these effects suggests that the ability of siRNA to RalA and RalB to increase p21 and
mdm2 and to decrease survivin levels is dependent on their ability to increase the levels
of p53. This also indicates that the p53 induced following RalA or RalB depletion was
functional and able to regulate the transcription of its target genes. Furthermore, the
ability of Ral siRNAs to regulate the expression of the p21, mdm2 and survivin genes in
a p53-dependent manner has important consequences on the ability of Ral GTPases to
contribute to malignant transformation (see more below). In cells that lack both p53
alleles such as Calu1 cells, depletion of RalA or RalB failed to affect p21 and survivin
expression, further confirming the dependency of the Ral proteins on p53 to regulate the
expression of these genes. Our results also suggest that K-Ras regulates the expression of
p21 in a p53-dependent manner. However, the effects of K-Ras depletion on survivin
appear to be p53–independent in Calu-1 cells.
Depletion of RalA and RalB as well as K-Ras resulted in a significant increase in
its half life. This increased p53 stability is specific in that depletion of K-Ras, RalA and
RalB increased the mdm2 protein levels with little affects on its half life. Consistent with
this, depletion of RalA and RalB resulted in an increase in the levels of p53 Ser-15
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phosphorylation which has been associated with p53 stability43, 44. Taken together, these
observations suggest that depletion of RalA and RalB results in increased p53 Ser-15
phosphorylation and a more stable p53 that was able to induce the expression of p21 and
mdm2 and down regulate the expression of survivin. Depletion of these GTPases could
also affect other phosphorylation sites on p53 that affect its stability. Indeed, cellular
stress and DNA damage induce p53 phosphorylation at Ser-15 as well as Ser-20 and Ser37 which affect p53 stability by preventing its ubiquitination and degradation

43, 44

.

Therefore, investigations determining the effects of RalA and/or RalB depletion on p53
post-translational modifications other than Ser-15 are warranted to further understand the
mechanism by which depletion of RalA and RalB stabilizes p53. Finally, mt K-Ras was
shown to decrease the stability of p53 by activating the E3 ligase SNAIL which
ubiquitinates p53 and targets it to proteasomal degradation 16. It is therefore possible that
depletion of RalA and/or RalB inhibits SNAIL as well as mdm2 E3 ligases leading to less
ubiquitination of p53.
The effects of depletion of the Ral GTPases on anchorage-dependent and independent growth, invasion, apoptosis and proliferation have previously been studied
29, 33

. However, the mechanisms involved are not known and the contribution of p53 to

these effects is not known. Here we show that depletion of RalB inhibited cell cycle
progression by decreasing the proportion of cells reaching S phase and by increasing the
proportion of cells in both G1 and G2/M phases of the cell cycle. The ability of RalB
depletion to decrease the proportion of cells in S phase is rescued by p53 siRNA as well
as p21 siRNA suggesting that RalB depletion induces p53 and p21 which contribute to
inhibition of cell cycle progression. Furthermore, depletion of K-Ras induces G2/M cell
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cycle arrest in a p53-independent manner. Therefore, the fact that depletions of K-Ras or
RalB resulted in an increase in p53 levels, yet the consequences on cell cycle progression
were different suggest that, in addition to affecting common genes such p53, each
specific depletion also differentially affected other genes. This is not surprising as it is
known that Ral GTPases are regulated in a Ras-dependent and -independent manner, and
that RalA and RalB themselves mediate different cellular effects. In addition to the cell
cycle effects, depletion of RalB and to a lesser degree RalA inhibits anchorageindependent tumor cell growth and invasion which were also rescued by p53 siRNA.
This suggests that in the absence of RalB the stabilized p53 is not only able to inhibit cell
cycle progression and to inhibit invasion but also contributes to inhibition of anchorageindependent tumor cell growth. Unlike cell cycle progression, depletion of K-Ras induces
apoptosis and inhibits anchorage-independent tumor cell growth and invasion in a p53dependent manner.
In summary, we have uncovered a novel molecular mechanism by which Ral
GTPases affect transformation.

Furthermore, we have provided a biochemical link

between Ral GTPases and the tumor suppressor p53 by demonstrating that the expression
of Ral GTPases is required for maintaining low levels of p53, and that down regulation of
the Ral proteins results in the stabilization and reactivation of p53.
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Chapter 5
Summary and Conclusions
K-Ras and Ral GTPases have been extensively studied for their role in driving
malignant transformation and maintaining various malignant phenotypes. Similarly,
down regulation of the tumor suppressor p53 and up regulation of the anti-apoptotic
protein survivin are prevalent in human cancer and contribute to various malignant
phenotypes. In this thesis, we investigated the role of K-Ras, RalA and RalB GTPases in
the regulation of survivin and p53 and the functional consequence of this regulation.
First, we demonstrated that the expression of K-Ras is required for the
maintenance of the high survivin levels in human cancer cell lines that harbor mutant KRas but not in human cancer cell lines that express wild type Ras. This observation was
made in cancer cell lines from different lineages, suggesting that the involvement of KRas in survivin regulation is mutation- but not tissue-specific. Knocking down K-Ras
expression not only reduced the basal levels of survivin but it also inhibited drug-induced
survivin, suggesting that K-Ras may mediate resistance to apoptotic or anti-proliferative
drugs partly by up-regulating the expression of anti-apoptotic proteins such as survivin.
While depletion of K-Ras reduced survivin levels, ectopic expression of
constitutive active (CA) K-Ras failed to induce survivin levels. This is somewhat counter
intuitive but it suggested that while the expression of K-Ras is required for maintaining
high levels of survivin, mutant K-Ras alone is not sufficient to drive the expression of
survivin. Though additional studies are required to reach a definitive conclusion, we
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speculate that one possible reason for this is that the cancer cell lines as well as the
immortalized cell lines that we used in these experiments already harbor many genetic
alterations, and that ectopic expression of CA K-Ras was unable to further increase the
levels of survivin. For example, the HPNE cells that were used in this project were
immortalized by hTERT and E6/E7/st, which are known to antagonize p53, and induce
the expression of survivin. The other possible explanation is that mutant K-Ras is one of
several key nodes of complex signaling networks that are all required for maintaining
high survivin levels in cancer cells. Therefore, removing one of the nodes such as
depleting K-Ras would compromise the integrity of the network and lead to reduction in
survivin levels. Consistent with explanation are recent studies that show that only coexpression of K-Ras with β-catenin was able to induce survivin expression. Therefore, we
conclude that mutant K-Ras is required for maintaining high survivin levels, but alone is
not sufficient to drive survivin expression.
Our studies also demonstrated that in T24 cells, a human bladder cancer cell line
with mutant H-Ras, depletion of H-Ras reduced survivin expression. In contrast,
depletion of H-Ras in the human breast cancer MDA-MB-468 cells that do not harbor
mutant Ras did not reduce the levels of survivin. The limited number of cell lines used
precludes making generalized conclusion but it appears that mutant H-Ras may also be
involved in the regulation of survivin. These results warrant further investigation to
determine whether only mutant H-Ras and mutant K-Ras are required for the
maintenance of high survivin levels, and whether reduction in survivin levels could be
used as a read out or surrogate biomarker to measure inhibition of mutant H- Ras and
mutant K-Ras.
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Our studies also demonstrated that the reduction in survivin levels following
depletion of K-Ras was rescued by the proteasome inhibitor bortezomib. This suggested
that the depletion of K-Ras leads to the proteasome degradation of survivin. The
mechanism by which depletion of K-Ras leads to proteasome mediated degradation of
survivin is not clear. We first reasoned that depletion of K-Ras might affect survivin
phosphorylation at Thr-34 and/or Ser-20 and leads to proteasome degradation.
Phosphorylation of survivin at Ser-20 has been shown to interfere with the binding of
XIAP to survivin. Since XIAP binding to survivin has been suggested to stabilize
survivin, we speculated that depletion of K-Ras might increase Ser-20 phosphorylation
and hence decrease the stability of survivin by interfering with the binding of XIAP to
survivin. Similarly, dephoshorylation of survivin at Thr-34 has been shown to reduce the
stability of survivin. We generated S20A, S34A and S20A/S34A non-phosphorylatable
survivin mutants as well as S20D, S34D and S20D/S34D phospho-mimic survivin
mutants and demonstrated that depletion of K-Ras was as efficient at reducing the levels
of all these mutants as it was at reducing wild type survivin levels (data not shown).
These results suggest that the ability of K-Ras depletion to decrease the stability of
survivin may not depend on the phosphorylation of survivin at Thr-34 and/or Ser-20.
Depletion of K-Ras has been shown to induce apoptosis in many, but not all,
cancer cell line that harbor mutant K-Ras. Furthermore, in one study using the HCT-116
isogenic colon cancer cell lines with and without mutant K-Ras, depletion of survivin
resulted in induction of apoptosis and cell cycle arrest selectively in the isogenic cell line
that harbors mutant K-Ras. We found that the presence of mutant K-Ras does not predict
that depletion of survivin will result in apoptosis. For example, while depletion of
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survivin induced apoptosis in A549 and H460 cells it fail to produce similar effect in
panc-1, miapaca-1 or sw1990 cells, yet all of these cell lines harbor mutant K-Ras.
Furthermore, depletion of K-Ras decreases the levels of survivin and induced apoptosis
in panc-1 as well as miapaca-2 cells. Yet, in these cell lines depletion of survivin itself
does induce apoptosis, suggesting that the decrease in survivin levels does not contribute
to apoptosis induction following K-Ras depletion in panc-1 and miapaca-2 cell lines. We
found that depletion of K-Ras also reduced the levels of XIAP, and this may contribute to
the induction of apoptosis following K-Ras depletion. Pro- or anti-apoptotic members of
the Bcl2 family do not appear to be involved since their levels were not affected by
depletion of K-Ras. Future study using gene expression profiling or proteomics that focus
on other survival and apoptotic proteins could give further insight about the molecular
mechanism by which depletion of K-Ras induces apoptosis.
Although survivin was dispensable for apoptosis in some human cancer cell lines,
we have showed that it plays critical role in other K-Ras-driven malignant phenotypes.
To this end, reduction of survivin following depletion of K-Ras might be beneficial to
inhibit K-Ras-driven invasion and metastasis, therefore future studies are warranted to
study the role of survivin inhibitors at inhibiting K-Ras driven malignant phenotypes.
While K-Ras has been shown to have multiple downstream effectors, the three
canonical downstream effectors Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral have been
extensively studied for their role in Ras-driven malignant transformation. Our studies
demonstrated that depletion of RalA and/or RalB but not Akt1/2 or Raf-1 decreased the
levels of survivin, and this suggested that Ral proteins may mediate the effects of K-Ras
on survivin. While the presence of mutant K-Ras in a human cancer cell line predicted
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whether depletion of K-Ras would result in decreased survivin levels, mutation of K-Ras
alone was not sufficient to predict the same for Ral protein depletion. We found that both
mutant K-Ras and wild type p53 are required for Ral depletion to result in decreased
survivin. This suggested that Ral regulation of survivin could be mediated by p53. In
deed, in H460 and A549 cells, co-depletion with p53 prevented the decrease in survivin
levels following RalA and/or RalB depletion. This is an important finding that not only
gave evidence that the ability of Ral proteins to regulate survivin may depend on p53, but
it also suggested a novel role for Ral as a potential regulator of p53. Our follow up
studies gave further support to this suggestion (see more below).
Although depletion of Ral A and Ral B individually did not affect the levels of
survivin in certain cells (wt Ras and/or mt p53), it is possible that the combined depletion
of Ral A and Ral B may affect survivin levels. Studies have shown that depletion of RalA
induces activation of RalB and vice-versa. Therefore, a compensatory mechanism could
be responsible for the lack of effect on the survivin levels when the Ral proteins are
depleted individually.
We also found that depletion of Akt1/2 or c-Raf by siRNA was unable to reduce
survivin levels suggesting that the Pi3K/Akt1/2 and c-Raf/Mek/Erk pathways are not
required for maintaining high survivin levels. However, it is important to point out that
Pi3K could still be involved since it is upstream of Akt1/2 and it has additional effecter
than Akt1/2. Therefore use of siRNA to Pi3K may help to delineate if Pi3K is required
for maintaining survivin levels in mutant K-Ras harboring cells. In contrast to this, since
we saw reduction of Erk activation following depletion of c-Raf, we believe that the
Raf/Mek/Erk pathway is not required to maintain high levels of survivin.
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Our studies that demonstrated that the decreased survivin levels following Ral
depletion required the expression of p53 (see above) suggested that Ral proteins may
regulate p53 levels. Indeed, we have found that depletion of Ral GTPases increases the
levels of p53 and this is majorly by affecting the stability of the protein. RalA and/or
RalB depletion leads to significant increase in the half-life of p53 as well as
phosphorylation of p53 at Ser-15. Phosphorylation of p53 has been used as a marker of
p53 stability and we believe that Ral GTPase may affect the stability of p53 by affecting
this phosphorylation site. While we used Ser-15 as a marker, our studies do not rule out
the possibility of other phosphorylation sites and other post-translational modifications
that are known to affect p53 stability. Therefore, future studies that investigate how
depletion of Ral proteins leads to increased p53 protein stability could give further insight
about the molecular mechanism.
The depletion of the Ral proteins resulted in increased levels of p53, and this p53
appears to be functional, as demonstrated by modulation of its target genes p21 and
survivin.

Indeed, depletion of Ral proteins led to increased expression of p21 and

decreased expression of survivin in a p53-dependent manner. Depletion of RalA and/or
RalB increased p53 levels in some cell lines more than did the depletion of K-Ras.
Furthermore, functionally while depletion of K-Ras interfered with cell cycle progression
at G2/M in a p53- independent manner, depletion of RalB affect cell cycle progression at
S phase in a p53-dependent manner. Therefore, we conclude that Ral GTPase may
regulate the levels of p53 in a K-Ras-independent manner in addition to K-Rasindependent manner.
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In this thesis, we also showed that depletion of Ral GTPases inhibited anchorageindependent growth and invasion in p53-dependent manner. Despite previous studies
that showed the importance of RalA but not RalB in anchorage-independent growth and
in-vivo tumor formation, in our studies we found anchorage-independent growth to be
potently inhibited in cells where RalB was depleted. Finally, We have recently shown
that ectopic expression of CA K-Ras V12, RalA 72L and RalB 72L down regulated the
expression of ectopically expressed p53 and inhibited its ability to up regulate the
transcriptional activation of the promoter of its target gene p21 in normal mouse embryo
fibroblasts. In contrast, ectopic expression of constitutive active RalB 72L in A549 cells
that already harbor mutant K-Ras, failed to reduce p53 levels (data not shown).
In summary, in this thesis we have provided evidence that some human cancer
cells require the expression of K-Ras and Ral GTPases to maintain high levels of survivin
and low levels of p53, and this appears to be mediated at least in part by mechanisms that
regulate the stability of both survivin and p53. Using several human cancer cell lines
from different lineages, we have discovered that in cells that harbor mt K-Ras and WT
p53, down regulation of K-Ras, RalA, RalB but not c-Raf and Akt1/2 leads to p53 Ser15
phosphorylation and a significant increase in its half life and stability as well as
regulation of p53 target genes (i.e. p21, mdm2, survivin) and inhibition of cell cycle
progression, soft agar growth and invasion.

Our data suggest that K-Ras and Ral

GTPases suppress p53 levels and their depletion increases p53 stability and reactivates it
to suppress malignant transformation. The following working model for the role of KRas and Ral in the maintenance of survivin and p53 protein levels is proposed.
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Figure 27. Role of K-Ras, RalA and RalB in the regulation of p53
and survivin. In cancer cells that harbor wt-Ras, regardless of the
mutation status of p53, depleting K-Ras, RalA or RalB by siRNA fails to
affect the protein levels of p53 or survivin. In cells that harbor mt-K-Ras
and mt-p53, depleting K-Ras reduces survivin protein levels but fails to
affect the levels of p53. On the other hand, in mt-K-Ras/wt p53
harboring cells, depleting RalA, RalB or K-Ras induces p53 and reduces
survivin protein levels.
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